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II. Eczematous and Immunologic Diseases 
Eczematous and immunologic skin diseases are among the 
most common clinical afflictions. They make a great physical 
and economic impact on our society. At times they can be 
devastating. 
Our understanding of skin disease has greatly advanced dur-
ing the past 15 years. Much of this progress can be attributed 
to major advances in knowledge relating to basic immunologic 
mechanisms. It has become clear that the skin is a target for 
diverse assaults by the immune system. Conversely, recent 
detailed study of skin diseases has added considerably to our 
understanding of basic immunologic mechanisms. There is gen-
eral agreement that greater understanding of these diseases, 
the elucidation of the pathogenesis of still others, and the 
development of useful therapeutic modalities rely upon a ra-
tional understanding and integration of immunological concepts 
and methods into the study of skin diseases. 
As almost all of the diseases discussed in this section relate 
to the immune system, which is extremely complex, it will be 
helpful to preface this report with a brief review of the mecha-
nisms that mediate immunologic injury. 
The Immune System. The basic constituents of the immune 
system are lymphocytes, antibodies, phagocytic cells (neutro-
phils, macrophages), and complement proteins. When foreign 
substances such as bacteria, viruses, fungi, or tissues from 
another individual, are introduced into an animal or human, 
that individual responds by mobilizing cells that can specifically 
react with the antigen and, by producing antibody (immuno-
globulin) molecules, can bind to and ultimately cause the .de-
struction of the antigen. The initiation of the immune response 
depends upon the interaction of antigen and 3 distinct cell 
types: (1) macrophages; (2) thymus-dependent (T) lymphocytes, 
and (3) bone marrow-derived (B) lymphocytes. Each has a 
distinct role in the immune response; however, coordination of 
their activity is required in order to achieve an optimal re-
sponse. 
T lymphocytes are derived from cells that mature within the 
thymus. Upon interaction with macrophage-processed antigens, 
those T lymphocytes that bear antigen-binding cell membrane 
sites are specifically activated. These T cells then perform 
several fun ctions: they secrete pharmacologically active sub-
stances (lymphokines) that modulate the function of other cells, 
they destroy cells bearing the foreign antigen, and they regulate 
antibody production by B lymphocytes. This regulation may 
serve either to increase or to decrease antibody production by 
B lymphocytes. 
B lymphocytes are the precursors of plasma cells and actively 
secrete immunoglobulin molecules that have antibody activity. 
B cell activation and proliferation, like that of T cells, depends 
on the binding of antigen to membrane receptors that are 
known to be immunoglobulin molecules. Antibodies (immuno-
globulins) are found in all extracellular fluids and bodily secre-
tions, such as tears and saliva. In humans there are 5 major 
classes of immunoglobulins: IgG, IgA, IgM, IgD, IgE. These 
have sepru·ate and important biological functions. Upon com-
bination with antigen, certain immunoglobulins activate the 
complement system, a complex arrangement of at least 19 
interacting proteins in serum. Activation of the complement 
system has many effects. These include (1) the direct destruc-
tion of antibody-coated cells, (2) neutralization of viruses, (3) 
production of local inflammation, and (4) increased efficiency 
of phagocytosis. 
Antibodies also bind to foreign substances, thus promoting 
the ingestion and degradation of these substances by neutro-
phils or macrophages. IgE antibodies bind to mast cells and/or 
basophils and, in the presence of antigens, initiate the release 
of pharmacologically active substances, such as histamine. 
1. ATOPIC DERMATITIS 
Prevalence and Severity 
Atopic dermatitis (also known by the less specific terms 
"eczema" and "neurodermatitis") is a chronic inflammatory 
skin disease that occurs most frequently in persons with a 
personal or family history of other allergic problems (e.g., 
asthma, hayfever). Atopic dermatitis is a very common disease 
with prevalence between 2% and 3% in children 1-5 years old 
and 0.7% for all ages. Approximately 120,000-150,000 new cases 
of atopic dermatitis will occur each year if the current United 
States birth rate continues. 
The natural course of atopic dermatitis is variable. Sixty 
percent of patients have onset in the fust year of life and 90% 
within the fust 5 years. Follow-up surveys of 15-20 years 
showed persistence of atopic dermatitis in approximately 60%, 
with the most severely involved more likely to retain the 
disease. Even during "remissions," affected persons are predis-
posed to develop dermatitis secondary to physical and chemical 
irritation: Thus, a significant proportion of occupational skin 
disease (e.g., hand dermatitis) occurs in atopic individuals. For 
this reason, individuals with atopic dermatitis are excluded 
from military service and need careful guidance in their voca-
tional choices. 
Disease severity ranges from dry, pruritic, easily irritated 
skin to total body weeping and erythema. Exacerbations inter-
fere with .sleep, work, and social relationships. Chronic involve-
ment may cause considerable occupational and cultural disa-
bility. 
The health care burden is substantial. In 1968, 4% of all 
pediatric outpatient visits at the USC-Los Angeles County 
Medical Center were for atopic dermatitis. Atopic dermatitis 
accounts for 5-20% of all dermatology clinic visits. In addition 
to health and manpower costs, the chronic, long-term consump-
tion of topical corticosteroids and other medications by these 
patients is a major medical expense. 
Occupational costs in terms of disability and vocational re-
training are also substantial. Prevalence figures represent only 
patients with overt disease; yet many, perhaps the majority, of 
adult cases are subclinical, and the disease is only revealed after 
exposure to occupational traumas that produce hand dermatitis 
and other features. It is estimated that 25-50% of occupational 
hand eczema (the leading occupational disease) occurs in atopic 
individuals. 
Prevention, Treatment, and Cure 
The cause of atopic dermatitis is not known. Atopic derma-
titis cannot be prevented or cured. Partial control of the disease 
can be achieved by the use of topical steroids and daily attention 
to general management measures (avoidance of exertion and 
overheating, avoidance of skin irritants, such as soap and water, 
wool clothing, etc.) 
The only effective medications are topical steroids (cortisone-
type drugs.) Unfortunately continued daily use of such com-
pounds causes many undesirable side effects. There are no 
satisfactory systemic medications. Recent trials of immune 
enhancement therapy with transfer factor and levamisole have 
been unsuccessful. Antibiotics are frequently used to control 
infections associated with atopic dermatitis; at best, these med-
ications only partially affect the disease. 
Complications of Atopic Dermatitis: Infection. Kaposi's var-
icelliform eruption is due to widespread superinfection with the 
virus of herpes simplex or vaccinia. It is by far the most 
commonly seen in patients with atopic dermatitis. Severe infec-
tion may warrant heroic support measures; such infections may 
be fatal in infants. Atopic dermatitis patients also are more 
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susceptible to infections with the viruses of molluscum conta· 
giosum and verruca vulgaris than are patients with other 
der:rnatoses. 
Colonization and infection with Staphylococcal aureus may 
produce pustules or abscesses and/ or increase the severity of 
the dermatitis. The skin of over 90% of patients is, in fact, 
colonized with this organism. 
Cataracts. The incidence of cataracts is high (up to 16%) in 
those who have had severe atopic dermatitis for many years. 
They are usually bilateral, develop rapidly, and involve the 
anterior superficial cortex. Their course can run parallel to or 
diverge from that of other dermatitis. Posterior subcapsular 
cataracts can also develop following long-term or chronic cor-
ticosteroid therapy in patients with atopic dermatitis. 
Ichthyosis. The frequency of ichthyosis vulgaris in those with 
atopic dermatitis ranges from 1.6 to 6.0%. Moreover, about 50% 
of persons with the autosomal dominant type of ichthyosis 
vulgaris also are atopic. The dryness of ichthyosis certainly 
predisposes to irritability of the skin. 
Generalized erythroderma. Atopic dermatitis accounted for 
4.5 % of the exfoliative dermatitis cases in a reported series. 
Hospitalization, complications of infections, deleterious corti-
costeroid effects, etc., very often follow upon these cases. 
Food sensitivity. Food sensitivity constitutes a special prob-
lem in infantile atopic dermatitis. Food allergy manifested as 
dermatitis may be present in the first years of life with a marked 
decrease after ages 3-5. Although offending foodstuff in infantile 
atopic dermatitis has been said to be causative in up to 25% of 
patients, only rarely is it proven. Skin tests to foods generally 
do not predict whether or not dermatitis will develop. Trials of 
food elimination and food challenge are the only sure test. 
Status of Research 
Immunology: Reaginic hypersensitivity and allergy. Atopic 
dermatitis is more often associated with bronchial asthma and 
allergic rhinitis than are other dermatoses. Generally the res-
piratory condition begins later than the skin condition and the 
dermatitis may recede as the allergic respiratory disease 
emerges. No rational explanation for this alternating pattern 
has been developed, and alternation is by no means constant. 
Because atopic dermatitis is related to allergic respiratory 
disease, and, because both diseases are frequ~ntly associated 
with skin test wheal and flare (Type 1) reactIOns to envrron-
mental allergens, atopic dermatitis was long considered to be of 
an "allergic" nature. In a large study approximately 80% of 
patients had positive skin test responses. More severely in-
volved patients have a greater number of positive responses. 
Association of atopic dermatitis and immediate skin test 
reactivity may not be relevant to the pathogenesis, however, 
When skin tests are positive, they are frequently not associated 
with atopic dermatitis. For example, many patients who show 
skin test sensitivity to grasses have no worsening of their 
dermatitis during hayfever season. 
The role of food allergy in atopic dermatitis is very difficult 
to assess. Clearly in some cases foods have been shown to be 
significant allergens, yet it is rare to demonstrate a flare-up 
when these allergens are ingested. The relationship of cow's 
milk to infantile eczema has been especially controversial. A 
recent report suggested that allergen avoidance (especially 
cow's milk) during the fu·st 6 months decreases the incidence of 
eczellla in high-risk infants and another study carried similar 
implications. Contradictory reports have also appeared. Clari-
fication of this issue will require studies of a large population, 
clear diagnostic criteria, well-controlled vaYiables, and long 
follow-up. Such a study is worthwhile, however, if the incidence 
of atopic dermatitis can be reduced in genetically-susceptible 
individuals. 
Humoral immunity. Soon after the identification of IgE as 
reaginic antibody, studies demonstrated that this immunoglob-
ulin was elevated in over 80% of patients with atopic dermatitis. 
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Subsequent studies have confrrmed these findings and have 
shown that the degree of serum IgE elevation tends to corre-
spond with severity of skin disease; studies correlating allergen-
specific IgE (RAST) tests with skin tests showed reasonable 
but variable concordance. 
Despite the presence of elevated IgE levels the pathogenic 
significance of IgE in atopic dermatitis is questionable. Every 
study has demonstrated that some patients with atopic der-
matitis have normal serum IgE levels, typical atopic dermatitis 
occurs in patients with Bruton's agammaglobulinemia, elevated 
serum IgE occurs in conditions not associated with atopic 
dermatitis, and serum IgE levels may remain elevated after 
clinical remissions of atopic dermatitis occur. With our present 
knowledge, increased serum IgE levels can only be considered 
a nonspecific feature of atopic dermatitis, and their measure-
ment provides very little practical diagnostic or prognostic 
information. 
Serum IgE, however, is only one part of the total body IgE, 
and elevated skin levels of IgE in both involved and uninvolved 
skin of patients with atopic dermatitis have been reported. It is 
possible that local cutaneous reactions of IgE with circulating 
or transcutaneous sources of antigen could be related to the 
inflammation and pruritus of atopic dermatitis. 
A recent report describes the presence of circulating, com-
plexed IgE in patients with atopic dermatitis. These findings 
raise the possibility that IgE, complexed either with antigen or 
with antiglobulins, might lodge in skin to produce disease. 
Cell· mediated immunity. There is evidence for defects in 
cell-mediated immunity in atopic dermatitis. Patients have 
increased susceptibility to unusually severe cutaneous infec-
tions with viruses (herpes simplex, vaccinia, molluscum conta· 
giosum, and Coxsackie AI6) . Patients have a decreased sensi-
tization rate to plants of the Rhus family and dinitrochloroben-
zene (DNCB) and decreased response to candida and strepto-
coccal (SKSD) antigens. We do not know whether the de-
creased delayed hypersensitivity in atopic dermatitis is a.local 
defect limited to reactions in the skin or whether there is a 
central failure ofthe immunocompetent cells that mediate these 
reactions. 
Many laboratory correlates of depressed cell mediated im-
munity fluctuate with the severity ofthe disease. T lymphocytes 
are depressed as determined by E rosettes, and although the 
results are varied, lymphocytes are generally hyporeactive to 
antigens (including candidin, tuberculin, and herpes simplex) , 
and to T cell mitogens. Decreased concanavalin-A, tuberculin 
and SKSD-induced leukocyte migration inhibitory factor and 
direct leukocyte migration inhibition and lymphocyte transfor-
mation to human dander have been reported (the opposite has 
also been noted) . 
Chemotaxis. Neutrophil chemotaxis has been studied in per-
sons with atopic dermatitis and found to be depressed; lympho-
cyte PHA responsiveness and monocyte chemotaxis were also 
decreased. Neutrophil chemotaxis was present in only the most 
severely involved; migration normalized within 48 hours as 
patients improved. Subsequently it was shown that plasma 
from severely involved atopic dermatitis patients can inhibit 
normal neutrophil chemotaxis and that more normal migration 
of atopic dermatitis cells can be obtained by incubating the 
cells with normal human plasma. 
Abnormal monocyte and neutrophil chemotaxis and serum 
inhibition of monocyte chemotaxis has been found in patients 
with atopic dermatitis. The nature of the chemotactic inhibitor 
is not clear. 
It seems reasonable to postulate that impaired chemotaxis 
might account for the frequent cutaneous staphylococcal infec-
tions in atopic dermatitis. A slowed neutrophil response, in 
combination with a defective epidermis heavily colonized with 
S. aureus, would promote sufficient bacterial proliferation to 
establish an effective nidus. 
Immune deficiency. Increased serum IgE in combination with 
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depressed CMI and an atopic dermatitis-like eruption has been 
noted in Wiskott-Aldrich syndrome, hyper-IgE syndrome of 
Buckley, and thymic alymphoplasia. The DiGeorge syndrome 
and some cases of Nezelofs syndrome begin with a combination 
of increased IgE and decreased CMI responsiveness and der-
matitis that resembles (but is not typical of) atopic dermatitis. 
It has been suggested that transient IgA deficiency in early 
infancy fosters later development of eczema and abnormally 
increased IgE. 
The association of deficient cell-mediated immunity and high 
serum IgE levels in atopic dermatitis and various immune 
deficiency syndromes suggests defective T -lymphocyte regula-
tion of IgE production. This concept, possibly basic to our 
understanding of the mechanisms underlying atopic dermatitis, 
is supported by animal studies that demonstrated high reaginic 
antibody production in T cell depleted rats. 
Physiology and Pharmacology: Pruritus. The hallmark of 
atopic dermatitis is the intense itching that induces the scratch 
response and at least worsens if not causes the skin lesions. 
Although low itch thresholds have been demonstrated in atopic 
dermatitis, the physiology of the itch response is not well 
enough understood to make this information useful. 
Vascular reactions. Altered vasoreactivity is indicated by 
facial pallor, reduced digital skin temperature, and an abnormal 
response to the cold pressor test. Stroking of the skin is followed 
by white dermographism instead of the normal red response. 
Although epicutaneous absorption of nicotinic acid esters 
produces erythema in normal subjects it yields a whitening 
reaction in patients with atopic dermatitis. Intracutaneous in-
jection of methacholine chloride (Mecholyl) in patients with 
atopic der.matitis produces blanching around the wheal instead 
of the normal reddening. A recent report demonstrated that 
white dermographism, nicotinic acid blanching, and delayed 
blanch with methacholine consistently occur in areas with 
dermatitic change, whether of the atopic or the allergic contact 
type and are not, therefore, specific. Although this report re-
quires confirmation, it suggests that the abnormal vascular 
reactions in atopic dermatitis are seconary phenomena, neither 
diagnostic nor enlightening as to the etiology of this disease. 
Sweat secretion. Patients report that wide swings in the 
status of their dermatitis depend on the degree and frequency 
of sweating. Whether sweat secretion in atopic dermatitis is 
unimpaired or disturbed is controversial. 
Significant increases in sweating responses to Mecholyl have 
been demonstrated in both males and females with atopic 
dermatitis, allergic rhinitis, or asthma over responses in nona-
topic controls. That local beta-adrenergic blockade with pro-
pranolol intensifies the sweat response to acetylcholine in nor-
mal subjects but not in atopic dermatitis patients is also con-
troversial. If true, it would give support to the theory that a 
feature of atopy is an imbalance in the normal antagonism 
between the adrenergic and cholinergic nervous systems. 
Sebum production. Skin surface sebaceous lipids have been 
shown to be deficient in atopic dermatitis. Transepidermal 
water loss is greater in patients with atopic dermatitis than in 
normal persons. This might be related to the inability of many 
with atopic dermatitis to maintain soft and pliable skin. . 
Histamine. Intramuscular injections of histamine have been 
known to produce a disproportionate rise of skin temperature 
in the flexural areas of patients with atopic dermatitis, although 
mere increased transudation of histamine into diseased skin 
could account for flexural predilection. Increased skin histamine 
in patients with atopic dermatitis is consistent with recent 
histological demonstration of increased mast cell numbers in 
lichenified plaques. 
Neurotransmitters. Acetylcholine levels were reported to be 
15 times higher than normal in atopic dermatitis skin; levels 
paralleled the severity of the dermatitis and remained ' high 
during remission. Elevated blood acetylcholine levels in chil-
dren with atopic dermatitis or asthma have also been reported. 
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Plasma noradrenaline is diminished and sometimes too low to 
measure in patients with severe atopic dermatitis. Noradrena-
line has also been shown to have a stronger affinity for the skin 
of atopic dermatitis patients than for that of normal subjects. 
Other mediators. A normal cutaneous response to prosta-
glandin El has been observed in atopic skin. Increased levels of 
blood kininogen have been reported in severe cases of atopic 
dermatitis. Abnormal reactions to intracutaneous kallikrein 
have been found in atopic dermatitis patients. It is unclear 
whether these phenomena are consequences of inflammation 
(see above) or primary events. Intracutaneous serotonin pro-
duced either no vasodilation or less vasodilation in patients 
with atopic dermatitis than in normal subjects. 
Cyclic nucleotides. Adenyl cyclase, phosphodiesterase, and 
cyclic AMP-dependent protein kinases are normal in the skin. 
Enzymes related to glucose metabolism are normal in isolated 
sweat glands of patients with atopic dermatitis. The level of 
epidermal cyclic AMP content in atopic patients is a controver-
sial subject; it has been reported as the same as in normal 
persons and as two times greater than normal. However, the 
cyclic AMP response to maximal stimulation with isoproterenol 
was similar in both groups. Inhibition of epidermal DNA syn-
thesis by .catecholamines is a function of ,B-adrenergic stimula-
tion. DNA synthesis in cultured epidermis from both affected 
and normal skin of patients with atopic dermatitis was normal; 
however, DNA synthesis in the patients was not suppressed by 
catecholamine as it was in the epidermal cultures from normal 
subjects, thereby demonstrating a relative ,B-adrenergic block-
ade in keratinocytes. 
More recently, 2 studies have demonstrated decreased ,B-
adrenergic responsiveness in both lymphocytes and polymor-
phonuclear leukocytes taken from patients with atopic derma-
titis; similar findings were obtained in patients with asthma. A 
significantly reduced PGE1 -induced cAMP response in patients 
with severe atopic dermatitis and a decreased histamine H2 
response of granulocytes from asthmatic patients have recently 
been shown. 
These studies indicate a defect not solely limited to the ,B-
adrenergic system. Abnormalities associated with histamine 
H2, PGE1, and ,B-adrenergic receptors might indicate a defect 
farther along a common pathway in atopic dermatitis. 
Regardless of the site, defective cyclic AMP responsiveness 
could result in a relative imbalance of the cyclic nucleotide 
regulatory system in atopic dermatitis. This could explain the 
clinical observations of cholinergic hyperresponsiveness. Cyclic 
nucleotide abnormalities among cells of the immune system 
could account for the multiple and varied physiologic, phar-
macologic, and immune defects that occur in atopic dermatitis. 
Ultrastructure: A recent study, in which 1 Jlm epon-em-
bedded skin sections were used, demonstrated, in addition to 
endothelial cell hypertrophy and basement membrane redupli-
cation, an increase in mononuclear phagocytes and in absolute 
numbers of mast cells in lichenified plaques. The number of 
mast cells in the plaques was almost twice that in clinically 
uninvolved skin or acutely inflamed skin of the same patients 
or in normal skin of nonatopic patients. Demyelination of 
cutaneous nerves was observed in chronic lesions. Whether 
neuronal changes are primary or secondary is still to be deter-
mined. 
Genetics: The incidence of atopic dermatitis is clearly influ-
enced by heredity. One recent study reported an incidence of 
only 2% in 754 offspring from nonallergic parents and as much 
as 27% in 94 infants who had allergic mothers. They developed 
atopic dermatitis in the first 3 months of life. Another study 
has shown that 58% of children developed atopic dermatitis by 
2 years of age if one parent had allergic disease and 79% if both 
parents were affected. 
Inheritance patterns have been interpreted variously as au-
tosomal dominant, autosomal recessive, and polygenic or mul-
tifactorial. Most evidence supports the view that atopic der-
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matitis has a polygenic inheritance and that both exogenous 
and endogenous factors influence the expressivity of the gene 
effects. Monovular twins have a tenfold greater chance of 
developing atopic dermatitis than do dizygotic twins. A search 
for associations between atopic dermatitis and genes responsible 
for the expression of histocompatibility antigens has been made 
but not found. 
Animal models: Canine reaginic allergy was first described 
in 1941 and has received sporadic attention since. This spon-
taneous canine atopic disorder primarily dermatological, causes 
intense pruritus with consequent excoriation and lichenification 
that may be related to environmental allergens entering via the 
respiratory route. The disease has distinct seasonal associations, 
although nonseasonal allergies to molds and house dust also 
occur. 
Diagnosis can be confirmed with skin tests and passive cu-
taneous anaphylaxis. The isolation and characterization of ca-
nine reagin has suggested analogy with human IgE. The disease 
appears to be genetically determined. 
Canine allergy offers a potentially valuable animal model for 
the study of mechanisms of atopic dermatitis. Considerable 
work is required to clarify immunologic abnormalities in these 
dogs and to delineate the genetics of the conditions. 
Needs for Additional Basic Research 
Pharmacologic and biochemical studies: Numerous studies 
suggest that abnormal responses to pharmacological agents in 
atopic patients may reflect a widespread cellular defect in many 
body tissues. Sensitive and accurate radio-immunoassays are 
now available for detecting many inflammatory mediators (his-
tamine, acetylcholine, kinins, prostaglandins, etc.) in atopic skin 
and plasma. Specific receptors (adrenergic, cholinergic, histam-
inic, etc.) empower cells to recognize mediators. We need to 
know if defects of receptors, rather than or in addition to 
abnormal levels of mediators, exist in atopic dermatitis patients. 
Immunological studies. Patients with atopic dermatitis have 
a constellation of immunological defects: elevated serum IgE 
levels, depressed cell-mediated immunity, and reduced or ab-
normal leukotaxis. In order to find out whether these immu-
nological abnormalities represent the primary defect or only a 
secondary response to inflammation, certain aspects of the 
problem have to be considered. 
Many patients with atopic dermatitis display cutaneous 
anergy. Why their skin fails to show normal antigenic responses 
is unknown. Is this deficiency related to local skin factors or to 
central immunological defects? Is IgE production regulated by 
specific T-cell subpopulations or by other controlling mecha-
nisms? 
New assay methods are available for cytotoxicity. Can these 
methods determine whether or not atopic dermatitis is an 
autohypersensitivity reaction to skin components? 
Many patients with atopic dermatitis have defective leuko-
~yte -chemotaxis. Better characterization of the chemotactic 
inhibitor present in the serum of these patients is necessary. 
Epidermal cells and murine T-cells have some of the same 
antigenic characteristics. The possibility that human T-cells 
and epidermal cells in atopic dermatitis have a common defect 
should be explored. 
Studies are needed on the production and regulation of 
cytokines, and on the effect of various inflammatory agents on 
the iInmunocellular interactions associated with atopic derma-
titis. Also, studies are needed to reveal the function of immune 
complexes found in the serum and deposited in the skin of 
patients with atopic dermatitis. 
Physiological and structural studies. The most constant but 
least understood features of atopic dermatitis are dry skin and 
pruritus. Basic studies are needed on the relationship of skin 
structure and function to atopic dermatitis. Very thin sections 
should be examined by both light and electron microscopy to 
deterTIline if there are distinctive histopathologic features pres-
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ent in the skin of patients with atopic dermatitis. Cell prolifer-
ation and differentiation of the epidermis should be studied by 
ultrastructural and biochemical methods. The hydration, 
permeability, and other physical characteristics of atopic epi-
dermis and stratum corneum should be better understood. The 
response of eccrine sweat glands to local pharmacological agents 
and the effect of sweating on atopic skin should be determined. 
Skin lipids should be measured in atopic patients to determine 
whether or not there is a characteristic lipid distribution in the 
disease. 
Itching, one of the most bothersome manifestations of atopic 
dermatitis, is also one of the most common of complaints. The 
pathogenesis of pruritus should be studied. We need to find out 
if this itching of atopic dermatitis is the result of elevated levels 
of pruritogens or of a reduced itch threshold of cutaneous nerve 
endings. 
Genetic studies: Atopic dermatitis has strong hereditary 
tendencies. Genetics, including HLA and other immunogenetic 
factors, should be studied to clarify the mode of inheritance, 
the disease homogeneity, and the relationship of atopic der-
matitis to associated heritable conditions, such as asthma, 
allergic rhinitis, and ichthyosis. 
Animal models: At present, the affected patient is the only 
proven model; restrictions on the use of humans make testing 
of new drugs difficult. Canine allergic dermatitis appears to be 
a potentially useful analog of atopic dermatitis. Research pro-
grams should aim toward more complete characterization of 
genetic, immunologic, pharmacologic, and cutaneous features 
of the diseased animals. Efforts to develop small and inexpen-
sive animal models should also be encouraged. Bordetella per· 
tussis immunization in mice produces changes in pharmacologic 
reactivity that seems to mimic human atopy. This should be 
explored further. Spontaneous dermatitis in certain strains of 
mice and rats should be evaluated as well. 
Cell and tissue culture: Studies on leukocytes taken from 
atopic dermatitis patients have shown that these cells have the 
same functional and biochemical responses to pharmacological 
agents (catecholamines, PgE" histamine) and those observed 
in vivo. These cell systems should be studied further. They 
may prove useful as indicators of molecular pathology and 
perhaps ultimately as predictors of the efficacy of therapeutic 
agents. New developments in skin culture methodology now 
makes possible the study ofthe proliferation and differentiation 
of epidermal cells in vitro. These culture techniques should be 
applied to the study of epidermal cell kinetics in atopic der-
matitis. 
Needs for Additional Clinical Research 
Atopic dermatitis is cyclic, and the pharmacological and 
immunological responses vary with the severity of the disease. 
Because of this, much research on atopic dermatitis should be 
carried out in clinical settings to define clearly the features and 
to evaluate objectively the extent and severity of the disease. 
Natural course: There is a need to establish the natural 
course of atopic dermatitis through long-term studies at centers 
that have both clinical and laboratory interest in the disease. 
Such knowledge would help to determine what therapeutic 
approaches are best and what disease manifestations are prog-
nostic. 
Infection: Staphylococcus aureus colonization is practically 
a constant feature of atopic dermatitis. We cannot eliminate 
colonization with the usual antibiotic therapy .. Therefore, we 
cannot rule out the possibility that S. aureus is a significant 
causative factor that may trigger inflammation through im-
munologic or toxic mechanisms. The basis for colonization, the 
incidence of infection, and possible pathogenic mechanisms 
should be studied. 
Viral infections should be studied also, particularly the re-
lationship of herpes simplex to atopic dermatitis. The role of 
viral infections in exacerbations of atopic dermatitis should be 
explored. 
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Prevention: Prospective studies should be encouraged, par-
ticularly in high risk infants, to discover ways to prevent the 
disease. Environmental antigens should be identified, and the 
effect of neonatal exposure to these antigens should be explored. 
Other aspects: Little is known about the relationship of 
emotional stress to atopic dermatitis exacerbations. Insight into 
such a realtionship might lead to a method for control of the 
disease. Rapidly developing bilateral cataracts are a complica-
tion associated with long-standing severe atopic dermatitis. The 
association and causation of cataracts and other ophthalmolog-
ical disease in atopic dermatitis should be studied. 
Therapy: Besides the possibilities of preventing atopic der-
matitis by allergen avoidance during the first few months of life 
and of controlling it through psychological methods, certain 
drug treatments deserve consideration. As for several other 
diseases covered in this report, there is a need for the develop-
ment of anti-inflammatory agents that lack the side effects of 
steroids. Topical and systemic antibiotics should be developed 
to achieve skin antibiotic levels high enough to eliminate colo-
nization with pathogenic S. aureus. Also, there is a need to 
evaluate drugs that affect cyclic nucleotide metabolism, such 
as anticholinergic agents and phosphodiesterase inhibitors. 
Topical cromoglycate has been reported as effective in atopic 
dermatitis. This and other chemical relatives require further 
evaluation. The new H2 antihistamines alone or in combination 
with traditional antihistamines may yield a much needed sys-
temic therapy, and their use should be explored. 
2. CONTACT DERMATITIS 
Dermatitis or eczema has a characteristic histology and mul-
tiple causes. When an external agent causes dermatitis, it is 
called contact dermatitis. If the external agent damages the 
skin's cells directly, it is called irritant contact dermatitis. In 
contrast, allergic contact dermatitis (ACD) is an indirect proc-
ess, resulting from immunological reactions to chemical aller-
gens (sensitizers). Sensitizers are found in almost limitless num-
bers in our environment. This immunological reaction is ac-
quired. It is principally of the delayed type. Common contact 
allergens are: nickel, chromates, the catechols of poison ivy and 
poison oak, synthetic chemicals, drugs, antibiotics, and cosmet-
ics. 
Prevalence and Severity 
The exact prevalence of contact dermatitis is not known. It 
is, however, among the greatest public health problems associ-
ated with environmental agents. Work-related skin conditions 
are the leading occupational diseases with an incidence of 45.6% 
nationwide in 1975, and the majority of these are due to contact 
dermatitis. 
The Oregon State Accident Insurance Fund (SAIF) insures 
55% of the approximately 1,110,100 members of the state's 
civilian labor force. Many large firms insure their own workers 
and are not obligated by state law to register their injuries with 
the state. In 1974, 27,644 of the 70,347 (39.2%) allowable and 
completed claims were for injuries confined to the skin. These 
cost the SAIF $6,037,471 for medical and administrative bills, 
8.3% of the monies (not including time-loss monies) the SAIF 
spent on all claims. 
In California all job-related injuries must by law be reported 
to the Occupational Health Branch as a socalled "doctor's first 
report," and skin diseases include contact dermatitis (both 
irritant and allergic), chemical burns, oil acne, chrome ulcers, 
scabies, etc., and exclude the large categories of cuts, lacera-
tions, scratches, and abrasions, which are called "injuries" and 
not "diseases." In 1975, California had 11,279 occupational skin 
"disease" claims. At least 95% of these skin diseases were 
contact dermatitis. These were 42.9% of all occupational disease 
2laims in California (26,290) for 1975. . 
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A large proportion of occupational and nonoccupational der-
matitis occurs on the hands. The 1971-74 Health and Nutrition 
Examination Survey found an overall prevalence of hand ec-
zema of 1.6 per 1,000 persons. In the 25-34 age group, the 
prevalence was 4.9 per 1,000 and 3.7 per 1,000 in the 35- 44 age 
group. Most hand eczemas seem to be irritant contact derma-
titis; only 17% of all hand dermatitis can be attributed to a 
specific allergen. 
A study such as the Health and Nutrition Examination 
Survey would probably fail to identify many people who occa-
sionally have acute ACD, which is usually a transient problem. 
It is possible, of course, that some ACD was hidden within 
diagnoses of atopic dermatitis, lichen simplex chronicus, num-
mular and dyshidrotic eczema. The figures cited above ob-
viously also grossly underestimate the real impact of dermatitis 
on the working force as they exclude homemakers, the largest 
group of uninsured and unpaid workers. Also excluded were 
members of certain industries that self-insure. 
In the total perspective of all skin diseases that occur in 
Americans working both within and outside of their homes, 
contact dermatitis is one of our major problems. Contact der-
matitis due to irritants and allergens is the most frequent 
occupational skin diesase seen by dermatologists. For some 
kinds of workers, contact dermatitis is a major hazard; indeed, 
its impact on their lives and pocketbooks is enormous. 
Prevention, Treatment, and Cure 
Clinical course: The allergic contact hypersensitivity, sensi-
tization can occur 7-10 days after the first contact with a potent 
allergen . or sensitizer. More often, however, allergy may not be 
manifested for many years. It is usually the result of repeated 
exposure to weaker allergens. Once contact allergy develops 
and as long as it persists, subsequent encounters with the 
allergen will produce dermatitis within 24-48 hours, depending 
on the potency of the allergen and the responsiveness of the 
sensitive person. The skin over the entire body is susceptible 
and contact any place will produce dermatitis, although the 
scalp and, to a lesser degree, the palms and soles are relatively 
resistant. 
The first signs of ACD are redness, swelling, and papuloves-
icles. These signs reflect activity at the cellular level. If the 
intercellular edema (spongiosis) progresses, vesicles develop . 
. These may burst, and an acute weeping dermatitis results, with 
intense itching as the dominant symptom. Initially the derma-
titis is confined to the site of allergen contact, and its distribu-
tion pattern may suggest its cause. In severe cases, dermatitis 
may spread to cover wide areas of the body. Frequently, hands 
and feet are involved simultaneously, although the primary 
exposure may have been only on the feet or the hands. The 
intensity of the dermatitis builds in severity for 4- 7 days. If no 
therapy is used and further contact with the allergen is com-
pletely avoided, the acute process often will progress to a 
subacute phase or to a short chronic phase before healing 
occurs. Healing often occurs within 1-2 weeks but may take as 
long as a month. In the chronic phase, it may be very difficult 
to separate a possible irritant dermatitis from an ACD with 
clinical and histological criteria. In both instances, the skin is 
red, thickened, scaly, fissured, and it itches. Irritant dermatitis 
may begin very rapidly (hours to days) with strong irritants, 
e.g., acids, alkalis. On the other hand, weaker irritants (cutting 
oils and even water) may require weeks or months to produce 
difficulty. 
Even though healing occurs, the contact allergy persists and 
reexposure to the offending allergen, even in very small 
amounts, can start the whole process over again. Some sensitiv-
ities, i.e., poison ivy/oak, may last most of a person's life. In one 
group of patients followed over a 3-year period, 50% of the 
people maintained their sensitivities, 25% lost them, and an-
other 25% developed new sensitivities. Primary irritant der-
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matitis, however, disappears quickly when the offending agent 
is avoided. Individuals prone to develop irritant dermatitis may 
have recurrent disease upon reexposure to a variety of irritants. 
Occasionally, neither irritant nor allergic contact dermatitis 
resolves spontaneously after an acute episode; instead, they last 
for months or years. There are several causes of chronic ACD. 
These could be a continued unsuspected exposure to allergens 
or compounds chemically related to the allergen. In some 
instances allergic contact dermatitis may be a response to 
therapy. An "atopic diathesis" could develop manifesting itself 
in vesicular or fissuring dermatitis of the hands and feet. (Both 
hands and feet are especially liable to chronic dermatitis.) 
There could be a superimposed infection, or the nature of the 
allergen or irritant itself could foster a chronic dermatitis 
(nickel, chromate, turpentine). 
If an allergen is easily identifiable and simple to avoid, the 
patient usually has no further problem. However, this is not 
often the case and the factors that produce relapses and chro-
nicity often prevail. 
Diagnosis: In some clear-cut cases of contact dermatitis, a 
quickly taken history can give information as to the origin of 
the difficulty. More often, however, a very careful history is 
needed. The development of contact dermatitis is closely re-
lated to people's work and leisure activities, and the history 
sought must reflect this association. A contact dermatitis his-
tory will include information about the following: family history 
of atopic dermatitis, childhood eczema or asthma, progression 
of the disease, occupation, hobbies, chemical exposure, cosmet-
ics, plant contact, previous topical treatment (doctor and pa-
tient initiated). 
It is obvious that the discovery of precisely what a person 
does in his life is most likely to explain his contact dermatitis. 
In the differential diagnoses of contact dermatitis, a large num-
ber of other conditions must be considered. 
The patch test: The patch test is the diagnostic aid of greatest 
worth in determining the specific causes of ACD. Patch testing 
is performed by applying suspect allergens on the intact skin in 
an effort to reproduce dermatitis at the site of the test. A 
positive test implies contact allergy to the tested substance. 
The test substance must be prepared in nonirritating concen-
trations, mixed in appropriate vehicles, and applied under se-
rniocclusive dressings that will hold the chemicals in place. The 
methods of applying and reading patch tests have not been 
fully standardized. 
The information gained from patch testing, which can be 
used to inform and treat patients with ACD, is only useful when 
interpreted by an enlightened observer; positive test results 
must be incorporated within the framework of the patient's 
history, clinical findings, and the course of the disease to avoid 
rnisin terpretations. 
Despite these complications, patch tests are of great practical 
value and help to find the cause of ACD in many patients. 
Through the use of the patch test, co-operative groups of 
dermatologists, such as the North American Contact Dermatitis 
Group (NACDG), have provided evidence that the most com-
mon sensitizers in North America at this time are nickel, the 
caine group of chemicals (such as benzocaine), chromate, para-
phenylenediamine (found in dyes), ethylenediamine (found in 
medicaments), and neomycin. If patch testing were better stan-
dardized, its methodology and the meaning of positive reactions 
more consistently taught, and efforts made to prevent or limit 
exposures to the most common offenders in our environment, 
we would be well on our way to reducing the disability associ-
ated with ACD. 
Patch testing is not without some risk. Some allergens appear 
to sensitize people just by patch testing. Parapheylenediamine, 
chromium, and tetramethylthiruam have entailed such a risk; 
plants, such as primula, have been indicated as well. The overall 
significance of this hazard is probably minimal and is certainly 
not sufficient to prescribe patch testing when it is indicated. 
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Patch testing is best done when the contact dermatitis is 
quiescent, since there is a hazard of "flaring up" the dermatitis 
during the acute phases. A means of diagnosing ACD without 
directly involving the patient should be devised. Some small 
progress has already been made in this regard. Patch testing 
has also been used as a means to identify allergens likely to 
cause ACD if introduced into common use. This predictive 
testing is done in several different ways and has prevented some 
potential allergens from appearing on the general consumer 
market. 
Pathology: Vasodilation, dermal edema, and perivascular 
mononuclear cells that may penetrate the epidermis, coupled 
with epidermal intercellular edema, are features characteristic 
of many forms of dermatitis, including ACD. In acute ACD, the 
dermal mononuclear cell response is especially vigorous and is 
associated with vesicle formation in the epidermis. Basophilic 
leukocytes often constitute as much as 5-15% of the infIltrating 
cells. Irritant dermatitis, on the other hand, usually accentuates 
epidermal destruction and includes more polymorphonuclear 
cells in its infIltrate. Subacute dermatitis may show acanthosis 
and hyper- and parakeratosis and, as it becomes chronic, the 
skin may become increasingly pigmented. It is unfortunately 
often impossible to separate ACD from irritant dermatitis his-
tologically or clinically. 
Current Status of Research 
Allergic contact dermatitis: Allergic contact dermatitis is a 
type of delayed hypersensitivity to in vivo formed conjugates 
of haptens and autologous carrier proteins. Much of what we 
know about cell-mediated immunity has been obtained through 
the study of allergic contact dermatitis in man and laboratory 
animals. 
Allergens bind to components present in skin; the organism 
recognizes this complex as foreign. It is uncertain to which 
specific component the allergen binds, i.e., to epidermal micro-
somes, to serum proteins perfusing the skin, or to particular cell 
surface proteins such as immune response gene-associated (Ia) 
antigens on epidermal Langerhans cells. The action of the 
allergen may be to deform the tertiary structure of the carrier 
so that the carrier molecule is no longer recognized as part of 
the organism. Thus, even metal atoms, such as nickel or mer-
cury, may sensitize the individual. 
Where the foreign nature of the antigen is recognized is not 
known. The concept of and evidence for peripheral sensitization 
has received considerable support, yet no direct evidence exists 
to show that T lymphocytes are sensitized by antigen in the 
periphery rather than . in the lymph node. That macrophages 
operate in T cell activation is unquestioned. That is, the mac-
rophages must, in some way, present antigen to the T lympho-
cyte. The genetic restriction of this type of sensitization has 
been demonstrated in most animal systems. Once the macro-
phages present the antigen, T cell proliferation ensues in the 
paracortical areas of the lymph nodes. At this time, the orga-
nism is said to be specifically sensitized. Then, on reexposure to 
antigen, sensitized T lymphocytes release pharmacological me-
diators (called lymphokines) , and an inflammatory reaction 
ensues. 
Whether cytotoxic effector cells are relevant in this reaction 
is unknown, nor is it known what the target cells might be. 
That a homeostatic mechanism is operative in many forms of 
hypersensitivity reactions is unquestioned; that is, there is a 
constant balance between effector and suppressor systems. The 
mechanism(s) by which the suppressor cells operate in contact 
hypersensitivity is still unknown. The inflammatory process 
that ensues is composed of only a small percentage of sensitized 
lymphocytes. Monocytes, basophils, and neutrophils are in-
volved as well. Unfortunately, knowledge of immunologic mech-
anisms involved in allergic contact dermatitis is segregated into 
many unconnected areas, and it is difficult to follow events 
from the initial exposure to the final inflamatory response. 
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Primary irritant dermatitis: Even less is known about the 
pathophysiology of primary irritant dermatitis. A primary irri-
tant is a substance that directly damages skin cells at the site 
of contact. At times, chemical properties of the irritant deter-
mine the nature of cellular damage. For example, organic sol-
vents alter skin by dissolving the surface lipids and by removing 
lipid components from keratinocytes. The salts of chromium, 
arsenic and other heavy metals precipitate and denature pro-
tein, thereby causing skin irritation. Salicylic acid and urea, 
among other acid substances, can chemically and physically 
reduce and thereby alter the keratinous layer of the skin. 
Substances such as soluble cutting fluids, alcohol, soap, and 
even water may cause irritation, usually after prolonged, re-
peated exposures. These are termed "marginal or mild irritant 
agents." 
Needs for Additional Basic Research 
Research is needed on both the afferent and efferent immu-
nological mechanisms involved in delayed hypersensitivity. 
Special emphasis should be placed on allergic contact hyper-
sensitivity. Following are some of the more important problems. 
Environmental substances or haptens in some way bind to 
skin components and are recognized as foreign. It is imperative 
to find out what factors are necessary for coupling of hapten to 
carrier protein and to discover the nature of the carrier protein 
itself. Studies supported in this area could eventually provide 
the means for actively interfering with the allergic process. 
Langerhans cells comprise a small proportion of the epider-
mal cell population and have recently been implicated in con-
tact allergy. They exhibit cell surface markers including Ia 
antigens, identical to macrophages. Whether or not Langerhans 
cells are functional in presenting haptens or hapten-altered-
cell-surface-proteins to lymphoid cells, thus initiating the im-
mune response, is not certain and needs further study. 
In vitro studies have demonstrated that haptenated epider-
mal cells can be targets for specific lymphocyte-mediated cel-
lular cytotoxicity. We need to find out whether or not epidermal 
cells in vivo can also be targets for cytotoxic lymphocytes. 
In the lesions of contact dermatitis, from 5 to 15% of the 
cellular infiltrate is composed of basophils, and degranulation 
occurs in mast cells. The functions of mast cells and basophils 
in the dermatitic reaction are unknown and deserve further 
study. Specific antibodies are often detected along with specif-
ically sensitized lymphocytes. The function of these antibodies 
is also unknown. 
Many studies have explored the immunogenetic control of 
allergic contact sensitization in animals. It is now appropriate 
to support studies in this area on humans. 
To differentiate allergic contact dermatitis from primary 
irritant dermatitis often is quite difficult. A simple assay should 
be developed for differentiating these 2 disease entities. 
Some substances may be more potent allergens than others 
because the stratum corneum may provide less of a barrier to 
their entry. Basic studies should be supported on permeability 
factors in relation to the hazards of particular substances. 
Needs for Additional Clinical Research 
Studies should be supported to determine if tolerance to 
common environmental antigens can be induced by administra-
tion of chemically-related substances or by administration of 
the substance in very small doses over long periods of time. 
Some success has been achieved in producing hyposensitization 
to poison ivy/ oak; this procedure needs elaboration and refine-
ment. There are some diseases, such as mycosis fungoides, 
where treatment with a topical agent, such as nitrogen mustard, 
is very effective. Unfortunately, contact hypersensitivity almost 
always results. The development of methods for inducing hy-
posensitivity in these patients is needed. 
Patch testing is the best method that we have to identify 
allergic contact reactions, yet this method is not foolproof, 
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interpretation is subjective, and the technique is not without 
risk. Further development and standardization of patch testing 
methods are imperative. Better yet would be discovery of a 
means of diagnosing ACD without directly testing the patient's 
in vivo response. The search for in vitro correlates of ACD 
should be continued. 
Protection fron environmental allergens can be accomplished 
both by avoidance and by protective measures. Research should 
be supported to develop barrier creams, ointments, and films 
that prevent the penetration of common allergens or deactivate 
them by changing them chemically. 
3. URTICARIA AND ANGIOEDEMA 
Circumscribed raised erythematous areas of edema that in-
volve the superficial portions of the dermis are known as 
urticaria (hives). When the edematous process extends into the 
deep dermis and/or subcutaneous layers, it is known as angioe-
dema. Urticaria and angioedema may occur in any location 
together or individually, although angioedema commonly af-
fects the face or the distal portion of the extremities. The 
individual lesions arise suddenly, rarely persist longer than 24 
or 48 hours, and may continue to recur for indefinite periods. 
Episodes of lesions of less than 4 to 6 weeks duration are 
considered acute, whereas those persisting longer are termed 
chronic. 
Prevalence and Severity 
Urticaria and angioedema are common. More than one-fifth 
of the population has experienced some type of urticarial erup-
tion; of a group of college students, 15-20% had experienced 
urticaria or angioedema. One to 2% of the patients in general 
dermatology practice are seen because of urticaria or angioe-
dema. 
In over 70% of cases the etiology of chronic urticaria is not 
discovered. In some cases, urticaria may reflect an underlying 
serious systemic illness and in others it may become psycholog-
ically debilitating. Although persons of any age may experience 
urticaria or angioedema, the highest incidence is in young 
adults. Angioedema, with the notable exception of hereditary 
angioedema, is frequently associated with urticaria. In a study 
of 554 patients, 49% had urticaria/angioedema, 11 % angioedema 
alone (3 of these were of the hereditary type) and the remaining 
40% had only urticaria of various types. 
The natural history of urticaria and angioedema is not well 
documented. One study shows 50% of-patients still experienced 
clinical symptoms after 5 years, and, after 20 years, 20% of 
patients were afflicted intermittently. 
Prevention, Treatment, and Cure 
Idiopathic urticaria: The cause is usually unknown. Since 
this clinical entity is common, runs a capricious course, and is 
easily recognized, it is frequently associated with concomitant 
events. However, such attributions must be made with utmost 
caution. Although fungal infections, foods, medications, meta-
bolic and hormonal abnormalities, malignant conditions, and 
emotional factors have all been claimed as causes, definite proof 
of their etiologic relation usually is lacking. Unfortunately, this 
chronic form of urticaria/angioedema is not only a common 
disorder but also a poor respondent to available therapeutic 
modalities. 
Immunologic associations: Seasonal urticaria or angioedema 
occurring in individuals with a personal or family history of 
asthma, rhinitis, or eczema is often termed atopic and is pre-
sumed to be IgE-related. However, it is not known why only 
certain patients have hives in response to stimuli that typically 
cause respiratory symptoms. Drug reactions, such as penicillin 
allergy, can manifest themselves with urticaria and/or angioe-
dema and are similarly IgE dependent whereas in serum sick-
ness urticaria associated with fever, arthritis, enlarged lymph 
glands, and renal abnormalities may be mediated by both IgE 
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mechanisms or by complement dependent IgG. Allergic reac-
tions to foods commonly present with urticaria or angioedema. 
Skin testing to foods results in a high incidence of false positive 
reactions that do not correlate with the patient's symptoms and 
false negatives that may fail to reveal allergy to a food. Certain 
infections, particularly those caused by parasites (helminths), 
are associated with markedly elevated IgE levels and may also 
occur in conjunction with Ulticaria that appears to be IgE-
dependent. It is important, in these cases, to distinguish be-
tween urticaria caused by the underlying disease and urticaria 
induced by therapy or other factors. Episodes of chronic urti-
caria have been recognized as a presentation of underlying 
cutaneous necrotizing vasculitis. Urticaria or angioedema may 
also be manifestations of other systemic diseases, such as the 
"collagen-vascular" disorders. An allergic or immunologic 
mechanism should be suspected as the underlying cause. 
Nonimmunologic drug-induced causes: Urticaria may occur 
secondary to the ingestion of aspirin. The bulk of evidence 
suggests that these reactions are not immunologic. Such aspirin-
sensitive patients frequently do not tolerate other drugs, such 
as indomethacin, aminopyrine, or mefenamic acid, and also 
react to coal tar derivatives, such as tartrazine yellow #5 used 
to color foods and medication capsules. Certainly, when con-
fronted with a patient who has a history of urticaria associated 
with a long list of medications, a search must be made in his 
medications and diet for an offending substance. Some of the 
above chemicals are inhibitors of an enzyme called cyclo-oxy-
genase; aspirin may directly acetylate and thereby inactivate 
this enzyme. Thus an intrinsic susceptibility to the pharmaco-
logic or chemical properties of these agents may account for 
the urticaria. It is of interest that approximately 15% of aspirin 
sensi t ive patients are also sensitive to food additives, such as 
tartrazine yellow #5, and tartrazine sensitivity in patients with 
chronic urticaria of unknown cause has been found in 8% of 
patients examined. 
Metabolic causes: Hereditary angioedema is a distinct entity 
that is related to a metabolic disorder. It is a familial disease 
that is potentially fatal and is associated with episodic swelling 
of t he face and extremities. Patients may also have tongue, 
throat, or laryngeal swelling; the last abnormality can result in 
death by asphyxiation. In addition, they can have swelling 
about their intestines, causing severe abdominal pain that can 
mimic a surgical emergency. The disease has been shown to be 
secondary to a hereditary deficiency of a particular plasma 
protein, which is called the inhibitor of the activated first 
component of complement of cr INH. 
There is also a nonfamilial form of angioedema associated 
with lymphoproliferative disorders that may simulate heredi-
tary angioedema; it is unaccompanied by a deficiency of cr. 
There is, however, a striking reduction of the early components 
of the complement system, including cr, in this nonfamilial 
disease. 
Physical urticaria: Dermographism is a linear wheal with a 
flare reaction which appears on the skin after it is briskly 
stroked with a firm object. A transient, pruritic wheal appears 
rapidly and then usually fades within 30 minutes. This disorder 
has a prevalence of 4.2 %. Elevations in blood histamine levels 
have been documented in some patients after extensive exper-
imental stroking, and the dermographic response has been 
passively transferred to the skin of normal subjects with serum 
IgE. 
Pressure urticaria appears as deep, often painful, erythe-
matous local swellings that arise immediately or from 4 to 6 
hours after constant pressure has been applied to the skin. The 
urticaria may be induced by tight garments, such as the elastic 
in socks, tight wrist bands, belts, or brassiere straps, or by such 
sustained pressure as sitting. The histologic alterations in the 
delayed form of pressure wi;icaria include an infiltrate of mono-
nuclear cells that mayor may not be accompanied by eosino-
phils. Immunofluorescence studies have not detected immuno-
globulin or complement proteins, and the cause is essentially 
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unknown. The disease responds poorly to antihistamines; corti-
costeroids are sometimes needed. 
Vibratory angioedema was described in a family with an 
autosomal dominant pattern of inheritance. An induced exper-
imental attack was associated with transient rise in plasma 
histamine. 
Acquired cold urticaria is a disorder in which patients ex-
perience an urticarial eruption that may evolve into angioe-
dema. It has been associated with shock. For example, total 
body exposure, such as a swimmer experiences, can result in 
hypotension, fainting, and death by drowning. Attacks occur 
within minutes after an appropriate challenge, such as cold 
foods or liquids, the application of ice, and changes in ambient 
temperature. Passive transfer of cold urticaria to th e skin of 
normal recipients has been documented. Thus, in some cases, 
it is clearly an IgE-mediated reaction . The release of the mast 
cell-derived mediators, histamine, eosinophil, neutrophil che-
motactic factors, and degranulation of mast cells after cold 
challenge have been observed. 
Familial cold urticaria has been described in 2 forms; both 
are dominantly inherited. In the immediate form, the eruption 
occurs usually as erythematous patches rather than wheals and 
is associated with burning. Pyrexia, arthralgias, and a leukocy-
tosis of neutrophilic leukocytes occur during attacks. Passive 
transfer with serum has been negative. A delayed form occurs 
as deep erythematous, edematous swellings at 9 to 18 hrs after 
cold challenge. Lesional biopsy specimens show edema with 
minimal numbers of mononuclear cells; mast cells are not 
degranulated; complement proteins, immunoglobulins, and fi-
brin were not detected. Cold immersion does not release hista-
mine. The condition cannot be passively transferred with either 
serum or tissue extracts to the skin of a monkey, and the 
underlying defect has not been identified. 
Solar urticaria arises from exposure to the sun or to an 
artificial ligh t source. It results in pruritus and erythema with 
t he formation of wheals and angioedema and occasionally with 
syncope. Skin lesions developed under experimental conditions 
in response to various wave lengths of light are classified into 
six types. In two of the types, elicited by wave lengths of 285-
320 nm and 400-500 nm, th e response can be passively trans-
ferred to the skin of a normal recipient. 
Cholinergic urticaria, known also as generalized heat urti-
caria, develops after an increase in body core temperature, such 
as that induced by a warm bath, a warm shower, exercise, or 
episodes of fever . The eruption appears as pruritic, 1-2 mm size 
wheals that are surrounded by large areas of erythema. Syn-
cope, wheezing, and abdominal pain may occasionally occur. 
The injection of cholinergic agents, such as methacholine chlo-
ride, into the skin reproduces locally the clinical symptom 
complex in the flare area of the wheal. After challenge by 
exercise, elevations in plasma histamine have been noted. 
Heat urticaria is a rare form of urt icaria. Wheals develop 
within minutes at heated skin sites. Passive transfer has been 
unsuccessful. 
Although the various forms of physical urticaria occasionally 
occlli' together, th ey are not triggered by a single mechanism. 
Dermographism and pressure urticaria are frequently noted in 
the same individual; cholinergic urticaria has been observed in 
patients with acquired cold-induced urtical'ia; and dermograph-
ism and an increased sensitivity to vibratory stimuli have been 
reported in some pat ients with cholinergic urticaria. 
Status of Research 
Mast cells and basophilic leukocytes: Mast cells are found 
predominantly in the skin, respiratory tract, and gastrointes-
tinal tract and are derived from mesenchymal precursor cells. 
There are 7,000 to 12,000 mast cells pel' mm3 in normal human 
skin . Human skin mast cells are distinguished from respiratory 
tract mast cells by prominent villous extensions of the plasma 
membrane, granules that contain crystalline la ttices, and nu-
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merous microfllaments. The charactristic metachromasia of 
mast cell granules is due to their heparin content. 
The basophil, a polymorphonuclear leukocyte derived from 
the bone marrow, differs from the mast cell in embryonic origin, 
in content of intracellular proteoglycans, and in immunobiologic 
functions. Basophils circulate in the peripheral blood and are 
present in increased numbers in atopic persons. The granules 
of the basophil are metachromatic owing to their content of 
chondroitin and dermatan sulfates. 
In mast cells or basophilic leukocytes, the bridging of at least 
2 IgE molecules by antigen results in the coupled processes of 
activation and secretion. This requires the alteration of trans-
membrane and intracellular calcium ion fluxes, the uncovering 
of a serine esterase, and the use of energy-dependent processes. 
These biochemical events are regulated by the cyclic nucleo-
tides, 3'5'-cyclic adenosine monophosphate (c-AMP) and 3'5'-
cyclic guanidine monophosphate (c-GMP). Materials known to 
elicit specific IgE antibodies and subsequent mast cell-depen-
dent immediate-type hypersensitivity reactions in humans in-
clude proteins, polysaccharides, and haptens. (Haptens are 
simple chemicals and are the major antigens encountered in 
medical practice.) IgE-dependent reactions may occur after the 
entry of antigen by any route. 
The antigen-induced release of mediators can be demon-
strated in vitro in skin and in peripheral blood basophils after 
passive sensitization with IgE-rich serum. The release of me-
diators from lung is strikingly reduced below 37°C, whereas 
histamine release in human skin is maximal from 29°C to 37°C. 
Mediator release at temperatures below 37°C in skin is note-
worthy in view of the fact that peripheral skin temperatures 
are normally much lower than 37°C. The biologic and phar-
macologic modulation of mediator release from skin and lung 
are similar; however, disodium cromoglycate, an agent that 
suppresses histamine release from human lung, fails to suppress 
the IgE-mediated histamine release from human skin. 
Chemical mediators: Mast cells contain histamine, factors 
chemotactic for eosinophils and neutrophils, the proteoglycan 
heparin, and the enzymes chymase, arylsulfatases A and B, and 
N-acetyl b-D-glucosaminidase. Those substances have been 
partially characterized in rat and in human mast cells. Human 
or rat basophils contain histamine and uncharacterized factors 
chemotactic for eosinophils and neutrophils; arylsulfatases have 
been found in rat leukemic basophils, and an arginine esterase 
has been described in the basophils. Both mast cells and baso-
phils participate in the generation of unstored mediators, such 
as slow reacting substance of anaphylaxis (SRS-A), platelet 
activating factor(s) (PAF), and arachidonic acid metabolites, 
perhaps through their interactions with other cell types. 
Histamine is a preformed amine contained in mast cells, 
basophils, and platelets in association with their granules. His-
tamine is formed from L-histidine and enzymatically degraded 
through oxidative deamination by histaminase or through 
methylation by histamine methyltransferase. The biologic ac-
tivities of histamine are expressed through two tissue receptors 
classified as HI or H2. Which receptors are present in a biolog-
ical preparation is determined by inhibition with standard 
antihistamine preparations (HI) or a new group of antihista-
minic agents (H2), namely burimamide, metiamide, and cimet-
idine. The human skin vasculature contains both HI and H2 
histamine receptors, and the venular response of increased 
permeability depends on both types of receptors. The actions 
mediated by H2-dependent reactions on the cellular elements 
of the inflammatory response include: inhibition of T -lympho-
cyte functions, depression of neutrophil and eosinophil chemo-
taxis to defined chemotactic factors, and suppression of the 
activation and secretory processes in mast cells and basophils. 
A group of chemotactic factors with specificity for eosinophils 
is derived from mast cells. The eosinophil chemotactic factor of 
anaphylaxis (ECF-A) from human lung contains two acidic 
tetrapeptides. The synthetic tetrapeptides can induce the ac-
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cumulation of eosinophils in skin in humans and experimental 
animals. The eosinophilotactic factors derived from human 
basophils have not been characterized sufficiently to define 
their relation, if any, to the mast cell-derived products. 
A factor that is chemotactic for neutrophilic polymorphonu-
clear leukocytes has been identified in the serum of patients 
with IgE-dependent acquired cold urticaria. This factor is of 
high molecular weight (HMW-NCF) and neutral isoelectric 
point and chemotactically attracts and deactivates neutrophilic 
leukocytes in vitro. The time course of release of HMW -NCF, 
which corresponds to that of histamine in cold-induced angioe-
dema, is compatible with the hypothesis that it originates in 
the mast cell. 
Heparin is an acidic proteoglycan. It is present in the mast 
cell granule of rats and probably in the mast cells of other 
species. Whereas mast cells contain predominantly heparin, 
basophils (harvested from patients with basophilic leukemia or 
from guinea pigs) contain chondroitin-6-sulfate and dermatan 
sulfate. 
There are several secondary mediators in mast cells. Slow-
reacting substance of anaphylaxis (SRS-A) is an acidic sulfur 
containing mediator that is inactivated by arylsulfatases. Some 
investigators consider SRS-A to be an oxidative metabolite of 
arachidonic acid and think it is formed via the lipooxygenase-
dependent pathway. SRS-A increases vascular permeability 
and contracts smooth muscle. 
Platelet-activating factors (P AF(s» are phospholipids re-
leased from human cell suspensions by IgE-dependent mecha-
nisms. P AF(s) appear to be a group of molecules as indicated 
by differences in size, enzymatic inactivation, and function. 
P AF(s) indirectly alter vascular permeability by directly acting 
on platelets to cause the secretion of histamine and serotonin; 
additional functions include platelet aggregation in vitro and 
local platelet accumulation in vivo. 
Mast cell activation in vivo: The participation of the mast 
cell in the pathological process in vivo can be inferred through 
analysis of morphologic alterations and through identification 
and quantification of mast cell mediators in tissues or biolOgic 
fluids. Morphologic assessment has shown that mast cell de-
granulation is the initial alteration in the skin of patients with 
acquired IgE-mediated forms of cold-induced urticaria. 
Two experimental methods have provided a means to study 
the function of IgE and its interaction with the mast cell. These 
are (1) the intracutaneous injection of specific antigen or anti-
IgE, and (2) the passive transfer of IgE antibody to normal 
recipients followed by local challenge with antigen (Prausnitz-
Kustner reaction) . The injection sites demonstrated a biphasic 
response with a transient pruritic erythematous wheal-and-flare 
reaction followed by a painful deep erythematous poorly de-
marcated area of swelling that persisted for 24 hours. Histologic 
studies of the early phase showed mast cell degranulation and 
edema, while studies of the late phase showed edema, infiltrat-
ing lymphocytes, monocytes, neutrophils, eosinophils, baso-
phils, and endothelial-cell damage. 
Elevated levels of blood histamine have been noted after 
experimental challenge of patients with certain forms of physi-
cal urticaria or after the administration of agents that degran-
ulate mast cells directly. Factors chemotactic for neutrophils 
and eosinophils have also been discovered in serum after ex-
perimental mast cell activation in patients with physical urti-
caria. A decrease in the content or discharge of histamine and 
in eosinophil chemotactic activity has been noted in peripheral 
blood basophils of some patients with chronic idiopathic urti-
caria. 
Needs for Additional Basic Research 
Sensitive and specific assays should be developed for the 
detection of antigens eliciting urticarial reactions. In particular, 
the identification of food and drug allergens is critical. Methods 
must be developed for distinguishing between immune and 
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nonimmune mechanisms in urticaria. In those patients for 
whom the inciting agent is known, the mechanism of lesion 
formation should be studied. 
Circulating immune complexes and tissue-fixed complexes 
should be looked for in immunologically-mediated urticaria, 
and the role of complement in mediating immunological urti-
caria should be sought. 
Animal and culture models of urticaria should be developed 
for laboratory study. If assay systems were developed for phar-
ITIacological mediators in skin and in the circulation, studies 
could be made on the release, the metabolism, and the effects 
of ITIediators on blood vessels. 
The mechanism by which certain prostaglandin synthetase 
inhibitors, such as aspirin, cause urticaria needs further study. 
The pharmacological mediator of such reactions should be 
identified, and the release of such mediators by various pros-
taglandin intermediates should be studied in patients with 
aspirin urticaria. These findings may have applicability to other 
forITIs of urticaria. The mediators of tissue swelling accompa-
nying hereditary angioedema and the enzymatic pathways for 
such mediators are incompletely known. Studies of such mat-
ters should proceed, as the findings may provide etiological 
clues for the many forms ofnonheredital·y, nonallergic recurrent 
angioedema. 
It may be that mast cells have an altered response in some 
urticarias. Comparative structural and functional studies should 
be made on mast cells from normal subjects and urticarial 
patients. Pharmacological agents that can modulate synthesis, 
release, and degradation of mediators should be sought out. 
Such agents would be useful in studying the mechanisms of 
urticaria. They might eventually be useful as therapeutic 
agents. 
Needs for Additional Clinical Research 
The major recommendation is long-term study of the natural 
history and tissue pathology of urticaria in large numbers of 
patients. The probable resultant correlations of the clinical 
patterns of disease and tissue pathology will be useful in defin-
ing the types of inflammation. 
Some urticarias can be regularly produced in susceptible 
patients in a research setting. It is essential to continue human 
urticarial research, and both physical and nonphysical wticar-
ias should be studied. The study of how cholinergic stimuli 
cause hives in patients with cholinergic urticaria could provide 
a link between the function of the central nervous system and 
hive formation and might increase our understanding of cholin-
ergic hyperresponsiveness in asthmatics. Cold urticaria has 
been a useful tool in the study of pathophysiologic mechanisms 
of urticaria and research should continue in this area. Urticaria 
associated ~ith parasitic disease would be a suitable model of . 
nonphysical urticaria. 
Studies should be supported to evaluate the efficacy of new 
therapeutic agents, particularly new anti-inflammatory agents, 
in urticaria. 
4. THE VESICULOBULLOUS DISEASES 
In 1964 it was reported that the sera of patients with pem-
phigus contain autoantibodies directed against epidermal anti-
gens and that these antigens are located at the site of the 
earliest histopathologic change. Since then considerable atten-
tion has been focussed on immunopathologic mechanisms in 
many of the vesiculobullous skin diseases of man. These dis-
eases include: pemphigus, bullous pemphigoid, cicatricial pem-
phigoid, herpes gestationis, erythema multiforme and dermati-
tis herpetiformis. Studies of these diseases has led not only to 
a better understanding of their immunopathologic mechanisms 
but also to the development of more rational approaches to 
t herapy. The pathology of these cutaneous diseases is so acces-
sible for study that fundamental questions in immunopathology 
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(i.e., how autoantibodies, immune complexes, cells, and media-
tors participate in local immunologic injury) can be readily 
considered. Although uncommon, the above-mentioned bullous 
diseases may be among the best choices of immunologically-
mediated diseases for intensive basic study. In this section, 5 of 
these diseases will be considered: pemphigus, bullous pemphi-
goid, herpes gestationis, erythema multiforme and dermatitis 
herpetiformis. Each ofthese diseases may have a quite different 
immunopathogenesis. 
Pemphigus 
Prevention, treatment, and cure: Pemphigus is a rare skin 
disease. It is a serious disorder and carries a grave prognosis. 
Pemphigus is characterized by flaccid, peripherally-extending 
noninflammatory bullae that, upon rupture, produce large 
weeping denuded areas of skin. The mucous membranes are 
commonly involved and are often the initial site of onset. The 
disease generally begins in the fourth and fifth decades of life, 
although well-documented cases have been described in the 
seventh and eighth decades and in children. Pemphigus has 
now been found in all ethnic groups and races. It is, however, 
more common in peoples of Jewish or Mediterranean origin. 
Pemphigus has been reported in association with several other 
autoimmune disorders, including systemic lupus erythemato-
sus, myasthenia gravis, thymoma, and bullous pemphigoid. T-
cell deficiency and chronic mucocutaneous candidiasis have 
also recently been reported in association with this disease. 
A possible genetic link has been suggested by the increased 
frequency of HLA-AIO and HLA-B13 in pemphigus vulgaris; 
these studies need to be verified and extended. Additionally, 
biopsy-prove;} pemphigus in family members has been docu-
mented. 
Histopathologically, pemphigus is characterized by intraepi-
dermal bulla formation with the loss of cohesion of individual 
epidermal cells (acantholysis). The roof and base of the blister, 
therefore, are composed entirely of epidermal cells. 
The earliest pathologic alteration that can be observed with 
electron microscopy is dissolution of the intercellular cement 
substance. This is followed by destruction of the desmosomes 
(intercellular bridges). Classification of pemphigus into super-
ficial and deep forms is dependent upon the histologic level of 
blister formation within the epidermis. Pemphigus vulgaris, 
the most common and most serious form of the disease, and 
pemphigus vegetans, a rare clinical variant, show deep supra-
basilal·, acantholytic intraepidermal separation. On the other 
hand, pemphigus foliaceus, pemphigus erythematosus and 
Brazilian pemphigus foliaceus or "fogo selvagem" are super-
ficial forms of the disease, with the acantholytic bulla forming 
high in the epidermis, usually in or near the granular layer. 
Although less common than pemphigus vulgaris, pemphigus 
foliaceus is a less serious form of the disease. 
The diagnosis of pemphigus is based upon presentation of 
flaccid weeping bullous lesions that demonstrate the above 
histological characteristics. Immunofluorescence methods are 
also extremely valuable in the diagnosis of pemphigus and often 
provide the fIrst clue. The fIndings of IgG and complement in 
the ICS of early acantholytic lesions are highly indicative early 
in the disease, when the lesions may be confined entirely to the 
oral mucosa. The presence of the ICS antibody in the serum of 
these patients is also highly suggestive of pemphigus. These 
tests are very useful as pemphigus is more responsive to therapy 
when detected early. 
For many years, the mainstay of therapy for pemphigus was 
systemic corticosteroids in large doses. Doses as large as 300 
mg per day were often required to control lesions, especially in 
patients with widespread involvement. The earlier immunoflu-
orescent detection of pemphigus has changed the prognosis, 
and the more severe phase of pemphigus is fortunately less 
frequent. ..
With the delineation of specific immunopathologic mecha-
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nisms in this disease, other forms of therapy, including im-
munosuppressive agents and gold, are now commonly em-
ployed, either alone or in combination with corticosteroids. The 
combined use of corticosteroids and immunosuppressive agents 
(or gold) has allowed the physician to use much lower steroid 
doses, thus avoiding serious side effects. 
Although pemphigus vulgaris still poses a threat to the life 
and well-being of patients, the prognosis of this disease has 
changed radically in the last 2 decades, primarily owing to 
earlier recognition and better forms of therapy. In the preanti-
biotic and precorticosteroid era, death during the fIrst or second 
year after onset occurred in approximately 50% of patients. The 
mortality rate is about 9-24% in several recent reports; the 
deaths generally are due to the adverse effects of treatment. 
Several groups have also reported long-term (2 years) clinical 
and serological remission in pemphigus vulgaris patients follow-
ing completion of high-dose corticosteroid and immunosup-
pressive therapy. However, fairly high morbidity from gastroin-
testinal bleeding, from osteoporosis, or from diabetes (all asso-
ciated with large doses of corticosteroids) still remains. 
Status of Research: Pemphigus is an autoimmune disease. It 
is characterized by serum antibodies directed against an inter· 
cellular substance (lCS) of epidermis and mucosa. This has 
been demonstrated by indirect immunofluorescence (IF) stain-
ing. Compelling evidence now exists to suggest that this IgG 
autoantibody is the . cause of the disease process. The ICS-
reactive antibody is present in all forms of true pemphigus, 
including pemphigus vulgaris, pemphigus vegetans, pemphigus 
foliaceus, pemphigus erythematosus and Brazilian pemphigus 
foliaceus or "fogo selvagem." By immunoelectronmicroscopy, 
these antibodies have been shown to localize primarily in the 
ICS areas. Titers of pemphigus antibodies also often reflect 
disease activity and are, therefore, sometimes useful in the 
assessment of therapy. Although rare, false-positive reactions 
do occur. The presence of ICS antibodies strongly suggests a 
diagnosis of pemphigus. 
IgG deposition in the ICS areas may be· found in virtually all 
pemphigus lesions. Complement deposition, on the other hand, 
occurs only in acantholytic areas of early oral and skin lesions. 
Early complemeOnt components (Clq and C4) and C3 have been 
demonstrated in ICS areas of early acantholytic lesions, fIndings 
suggestive of classical pathway activation. Properdin and factor 
B deposition have also been demonstrated, but much less 
frequently. 
The in vitro C3 staining method has revealed, however, that 
pemphigus antibodies do not appear capable of complement 
fixation, despite the presence of complement components in 
skin lesions and the fact that pemphigus antibodies are found 
in IgG subclasses that should fIx complement. Notwithstanding, 
total hemolytic complement is much lower in pemphigus blister 
fluids than serum complement levels and other serum and 
blister fluid proteins. Early complement component levels (C1, 
C4, and C2) im pemphigus blister fluids are reduced, in addition 
to hemolytic C3 and C5, fIndings also reflective of classical 
pathway activation of complement. 
Pemphigus blister fluids exhibit anticomplementary activity. 
Hemolytic C1, C2, C3, and C5 are inhibited and factors Band 
C3 are inhibited when pemphigus blister fluid is added to NHS. 
Sucrose density gradient ultracentrifugation (SDGU) and stan-
dard hemolytic complement assays showed that the pemphigus 
blister fluid anticomplementary activity is greater than 19S. 
Similar anticomplementary activity was present in 6 of 10 
pemphigus serums tested by SDGU; however, this activity 
sedimented at about 12-19S. 
Sera from many pemphigus patients have elevated '3II_Clq 
binding activity (ClqBA). A relationship between elevated 
ClqBA and disease activity is also apparent. Serum antibody 
titers and ClqBA can increase and decrease simultaneously in 
some patients. In others, increase in ClqBA always coincides 
with a precipitous decrease in antibody titer. This latter rela-
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tionship suggests that the observed ClqBA represents, at least 
in part, immune complexes containing epidermal antigens. 
Recently it has been reported that sera from active cases of 
pemphigus contain cryoproteins. These cryoprecipitates con-
tain IgG with pemphigus antibody activity, complement com-
ponents and other srum proteins, which further implies that 
immune complexes are forming . 
Recent studies on an organ culture system of normal human 
skin suggest that pemphigus antibodies induce acantholytic 
changes in the epidermis within 72 hours. This phenomenon, 
occurring in the absence of complement, suggests that the 
autoantibody alone is suffIcient to induce the process of acan-
tholysis. It was further demonstrated that the IgG fraction, 
purilied from pemphigus serum, is responsible for this process. 
These studies and EM changes similar to those in pemphigus 
have recently been confIrmed. 
An epidermal cell tissue culture system has shown that the 
acantholytic inducing effect of pemphigus antibodies is in-
hibited by soybean trypsin inhibitor. It is possible, therefore, 
that pemphigus antibodies, upon combining with an antigen on 
epidermal cell surfaces, induce the release of a serine esterase 
that may be the cause of acantholysis. If this hypothesis is 
correct, the release of enzymes without the interaction of other 
mediators would be a unique function for antibodies. When 
complement is added to this system, however, cell death ensues. 
These provocative fIndings obviously must be extended. 
Bullous Pemphigoid 
Prevl!ntion, treatment, and cure: Bullous pemphigoid (BP), 
and subepidermal blistering disease of the elderly, is character-
ized by tense, generalized bullae. These lesions may arise from 
inflamed or noninflamed skin. BP shows no sex or racial pre-
dilection. This disease, although occurring most frequently in 
elderly patients (over 60 years), has been reported in all age 
groups including, on infrequent occasions, children. Approxi-
mately 10-20% of BP patients have mucous membrane involve-
ment. 
Bullous pemphigoid is a self-limited disease. Recent experi-
ence suggests that the majority of BP patients once treated 
with adequate doses of immunosuppressive agents and/ or corti-
costeroids go into a prolonged remission; spontaneous long 
remissions have also been documented. 
Histologic examination of an early blister reveals a subepi-
dermal bulla. Two histologic types of BP blister formation are 
generally recognized: inflammatory-poor and inflammatory-
rich. Noninflammatory bullae contain a minimal perivascular 
cellular infIltrate consisting of a few mononuclear cells and 
eosinophils in a perivascular distribution. The inflammatory 
blisters, by contrast, comprise an extensive perivascular dermal 
infIltrate of eosinophils, mononuclear, and polymorphonuclear 
cells. The blister cavity frequently contains neutrophils and 
eosinophils. 
Electronmicroscopic studies disclose smudging, thickening, 
and interruption of the basal lamina integrity. The site of blister 
formation occurs at a level of the lamina lucida (the area 
between the cell plasma membrane and the basal lamina) . 
The diagnosis of bullous pemphigoid is based upon appear-
ance, the histopathologic demonstration of subepidermal bul-
lae, and the immunofluorescent fIndings. On purely clinical and 
histopathologic criteria, it may be diffIcult or impossible to 
differentiate between bullous pemphigoid and other subepider-
mal blistering diseases. Immunofluorescent testing, which can 
demonstrate basement membrane zone (BMZ) deposition of 
IgG and complement in tissues and the presence of circulating 
BMZ antibodies in the serum, is now the best method to 
establish the correct diagnosis. 
In most instances, bullous pemphigoid will respond to lower 
doses of corticosteroids (40-80 mg of prednisone daily) than will 
pemphigus. With the discovery of specifIc immunopathologic 
mechanisms, immunosuppressives (azathioprine and metho-
Nov. 1979 
trexate) have also been successfully employed, usually in com-
bination with corticosteroids, in the management ofthis disease. 
As in pemphigus, the combined use of immunosuppressives 
with corticosteroids makes possible lower dosage of the latter, 
thus reducing the incidence of steroid complications. 
The prognosis for life is much improved, although, as in 
pemphigus vulgaris, large doses of corticosteroids in elderly 
people involve great risks that can be undertaken only if the 
probable benefits outweight the possible hazards. 
The great majority of bullous pemphigoid patients have a 
self-limiting disease. The average course of immunosuppressive 
and/ or steroid therapy is 4-6 months. Thereafter, many pa-
tients may have a prolonged (2 years) clinical, immunohistolog-
ical, and serological remission. In the past, association of bullous 
pemphigoid with malignancy was generally accepted by clini-
cians despite the lack of data. Recent age-matched studies, 
however, have failed to support this contention. 
Status of Research Activities 
Like pemphigus vulgaris, bullous pemphigoid is considered 
to have an autoimmune etiology. Evidence has been uncovered 
in several laboratories that suggest that autoantibodies and 
complement activation may be factors in the production of this 
disease. Direct IF studies of the perilesional skin of BP patients 
demonstrate the deposition of all classes of irnmunoglobulins 
along the basement membrane. IgG is the most frequent class 
of immunoglobulin deposited. IgD and IgE are found infre-
quently. The deposition of immunoglobulin along the BMZ is 
accompanied by the deposition of both early and late comple-
ment components, properdin, factor B, fibrin and/ or fibrinogen. 
Deposits of fibrin and/or fibrinogen occur in approximately 60-
70% of patients, usually in the presence of heavy deposits of 
immunoglobulin and complement. 
Immunoelectronmicroscopic studies, in which horseradish 
peroxidase techniques are used, have demonstrated that the 
imrnunoreactants in PB are localized in the lamina lucida, i.e., 
the space between the epidermal basal cell and the basal lamina. 
There is evidence that these immunoreactants are also depos-
ited on the half desmosomes (those structures anchoring the 
basal cells to the basal lamina). 
Examination of the sera of bullous pemphigoid patients re-
veals the presence ofIgG anti-BMZ antibodies in approximately 
80% of cases of active disease. There is no correlation between 
the extent of the blistering disease, however, and pemphigoid 
antibody titer. In addition to IgG antibodies, IgA and IgM anti-
BMZ antibodies and, on rare occasions, low titer IgE anti-BMZ 
antibodies have been described. It has been noted that approx-
imately 70% of patients with bullous pemphigoid have increased 
IgE levels. Other studies suggest that, following treatment, IgE 
serum levels decrease; some as much as 10-fold. The significance 
of these observations is unknown. 
The majority of sera from bullous pemphigoid patients is 
able to fix complement to the BMZ. This complement fixation 
appears to occur predominantly via the classical pathway al-
though alternative pathway factors (factor B and properdin) 
appear to fix in vitro via the C3 amplification mechanism. All 
subclasses of IgG have been demonstrated in the BMZ anti-
bodies; complement fixing IgG, however, appears to be confined 
to IgG subgroup 3. 
In a recent study, the sera of approximately 20% of BP 
patients have elevated '3II_Clq binding activity (Clq BA). This 
ClqBA, presumably representing the presence of immune com-
plexes, usually correlated with the presenc~ of active disease. 
Whether these "immune complexes" assume pathogenic signif-
icance remains for future work to determine. 
Examination of the serum complement levels reveals that 
although the patients' serum complement is normal, there is a 
quantitative decrease in 7 of the 9 complement components in 
the blister fluid. In addition, immunoelectrophoretic studies 
demonstrated that factor B is in its activated (Bb) form and 
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that the third component of complement is in its activated B,A 
migratory pattern. 
Recent studies indicate that the blister fluids also contain 
high molecular weight anticomplementary activity and both 
neutrophil and eosinophil chemotactic activity. A thermostable 
chemotactic component in the blister fluid can be removed by 
prior absorption of the blister fluid with an antihuman C5 
antiserum but not with antihuman C3, suggesting that this 
chemotactic factor probably resides in the C5a fraction of the 
fifth component of complement. Evidence has been provided of 
the presence of the eosinophilic chemotactic factor of anaphy-
laxis (ECF -A) the blister fluid of BP patients. These data, taken 
collectively, provide considerable circumstantial evidence that 
a cause and effect relationship exists between immunoglobulin 
and complement deposition in BP and the genesis of this 
inflammatory blistering disease. Recently, a basic macromolec-
ular protein of skin BMZ (lamina lucida) has been isolated and 
partially characterized. This protein (m.w. approx. 31,000) ap-
pears to be the pemphigoid antigen since it is able to block 
pemphigoid antibody staining of normal human skin in IF 
techniques studies. Surprisingly, this protein is also detected in 
urine and saliva of normal people. 
Herpes Gestationis 
Prevention, treatment, and cure: Herpes gestationis (HG), a 
very pruritic, subepidermal blistering disease of pregnancy, 
occurs approximately once in every 10,000 deliveries. The dis-
ease may be more common, however, than this reported inci-
dence. HG is a widespread eruption composed of lesions that 
vary from erythematous, edematous, papules to large tense 
blisters. Severe cases show generalized blister formation; mild 
cases have only mild-to-moderate pruritus with a few erythe-
matous papules and edematous plaques. HG commonly in-
volves the abdomen and extremities; the palms, soles, back, and 
face may also be affected. Contrary to the implication in the 
name, the disease process is not associated with herpes viruses. 
The disease usually begins in the fifth or sixth month of 
pregnancy, although onset has been reported as early as the 
first trimester of pregnancy and as late as the immediate 
postpartum period. Exacerbations in the immediate postpartum 
period and at the time of the first few menstrual periods are 
common. The disease is generally self-limiting. However, in 
subsequent pregnancies, HG may begin earlier and be more 
severe. There are several reports indicating that the disease 
may re-exacerbate with the use of estrogen- and/or progester-
one-containing medications. Of prime concern to the physician 
is the welfare of the 'infant, as about 10% of pregnancies asso-
ciated with herpes gestationis result in fetal death. Most babies 
born of affected mothers are completely normal, although some 
have transient urticarial, vesicular, and bullous lesions. The 
exact incidence of affected children is unknown. 
Histologically, the features of HG are characteristic but not 
diagnostic. A perivascular infiltrate of varying intensity, com-
posed of histiocytes, lymphocytes, eosinophils, and few neutro-
phils, is found in the deep and superficial dermal plexes. The 
characteristic feature of this disease, however, is basal cell 
necrosis over the tips of dermal papillae. In addition to this 
prominent feature, there are varying degrees of dermal and 
epidermal edema. As in BP, vesicular lesions show subepider-
mal blister formation. 
Ultrastructural studies demonstrate varying' degrees of basal 
cell necrosis. The' earliest changes in clinically altered skin are 
marked vacuolar degeneration of the endoplasmic reticulum 
with mitochondrial swelling, More severe lesions are character-
ized by complete disruption of the basal cell plasma membrane 
with extracellular extrusion of the mitochondria, Their cellular 
organelles are found in the space between the epidermal cell 
plasma membrane and the basal lamina. These findings suggest 
that the blister formation in HG occurs as a result of basal cell 
degeneration and an accumulation of fluid between the basal 
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cells and the basal lamina. Ultrastructural studies of the normal 
appearing skin of immunologically-proven cases of HG may 
also demonstrate destruction of the basal cell plasma mem-
branes. 
A generalized subepidermal blistering skin disease during 
pregnancy should strongly suggest a diagnosis of herpes gesta-
tionis. As in bullous pemphigoid, routine histopathology shows 
only subepidermal bulla formation, a feature shared with many 
other bullous skin diseases. As in pemphigus and bullous pem-
phigoid, specific immunofluorescent tests, the observation of 
C3 deposited in skin lesions, and the presence of the C3 fixing 
factor in the serum (HG) are probably the best means of 
confirming the diagnosis. 
The treatment of HG is symptomatic. Pruritus is a major 
problem and demands immediate attention. In some instances, 
the simple application of topical steroids to the skin will alle-
viate symptoms. Others can be controlled with antihistamines. 
Most patients, however, have extensive cutaneous lesions with 
severe pruritus, the control of which may require systemic 
steroids. Control has been accomplished by giving the patient 
20-40 mgm of prednisone daily. The dosage is regulated to 
provide the patient with symptomatic relief; the therapy is 
continued into the postpartum period. Generally speaking, how-
ever, the disease usually disappears completely during the 6 
months following delivery. 
The infant's lesions are transient. They generally disappear 
during the neonatal period and demand no therapy. Long-term 
steroid therapy in the mother during pregnancy could theoret-
ically produce adrenal suppression in the child, although this 
does not a.ppear to be a significant clinical problem. 
Status of research: The etiology of herpes gestationis remains 
unknown, although, as in pemphigus and bullous pemphigoid, 
humoral immune mechanisms and complement activation may 
be causative. The specific humoral immune factor has not as 
yet been completely characterized; present evidence suggests 
that one factor is an IgG autoantibody that avidly fixes com-
plement. Direct IF studies of peribullous and urticarial lesions 
and of normal-appearing skin of HG patients have consistently 
demonstrated heavy linear deposition of C3 along the BMZ. 
Concomitant immunoglobulin deposition mayor may not be 
present. In fact, only approximately 40% of the patients with 
HG have BMZ deposition of IgG. IgA and IgM BMZ deposits 
have also been infrequently noted in patients with HG. 
BMZ deposition of properdin and factor B of the alternative 
complement pathway are frequently detected; Clq, C4, and C5 
less frequently . The collective results of direct IF studies from 
several laboratories indicate that heavy C3 deposition along the 
BMZ of HG skin is the hallmark of this disease. The IF findings 
may persist in these patients' skin for several months, or as long 
as a year after the lesions have resolved. 
Direct IF examination of the skin of some infants, born of 
HG mothers, have demonstrated heavy linear C3 BMZ deposits. 
This heavy C3 deposition has occurred in both normal and 
affected infants. C4 and C5 deposition along the BMZ of the 
skin of these infants has also been noted; however, thus far, 
there are no reports of concomitant immunoglobulin deposits. 
Immunoelectronmicroscopic studies, in which horseradish 
peroxidase was used, have demonstrated deposits of C3 
throughout the lamina lucida. IgG deposits have also been 
detected in a similar distribution, a distribution pattern like 
that in bullous pemphigoid (BP). A question that remains 
unanswered at present is what is the relationship of HG and 
BP. 
In several studies 10-20% of patients with HG had a detect-
able IgG serum BMZ antibody. The titer of this IgG BMZ 
antibody has varied. One patient had a titer of 320; most had 
lower titers. These HG sera, however, avidly fixed the comple-
ment (C3) along the skin BMZ in titers that almost always 
exceeded the IgG anti-BMZ antibody titers. In the majority of 
HG patients, it has been impossible to demonstrate an IgG 
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anti-BMZ antibody with routine IF techniques. In vitro C3 IF 
staining, showed the presence of a substance called the "HG 
factor" in the sera of most, if not all, of these HG patients. This 
factor is capable of depositing C3 along with BMZ of normal 
human skin as well as along that of heterologous skin. 
Further studies demonstrated that "HG factor" is an avid 
complement fixing IgG anti-BMZ antibody which is present in 
the serum of patients with HG but in such small quantities that 
it escapes detection by routine IF techniques. In light of this, it 
is likely that the heavy C3 BMZ deposition, so characteristic of 
all direct IF studies in HG, is the result of the activation of the 
classical complement sequence by an avid complement fixing 
IgG anti-BMZ antibody. 
Most sera of HG patients have shown normal complement 
levels. One recent report, however, has documented a significant 
hypocomplementemic phase during the height of a HG erup-
tion. This hypocomplementemic phase appears to be the result 
of depression of both classical and alternative pathway com-
ponents. 
Erythema Multiforme 
Prevention, treatment, and cure: Erythema multiforme is an 
acute inflammatory process with a wide range of presentations. 
The cutaneous manifestations may be only a few erythematous 
papules, or there may be a widespread erythema and bullous 
lesions. Widespread disease is often associated with extreme 
malaise. 
Erythema multiforme is a reaction pattern in the skin, whose 
cause is elusive and often unrecognized. Like other forms of 
cutaneous vasculitis, erythema may be associated with a wide 
variety of underlying causes such as infectious agents, drugs, 
and malignancies. Bacteria, fungi, mycoplasms, and viruses are 
common causes. Viruses commonly associated with the disease 
include herpes simplex and enteroviruses, such as coxsackie and 
echo. Other recently associated infectious agents are milkers 
nodules and infectious mononucleosis. Stevens-Johnson syn-
drome is a severe form of erythema multiforme that occurs in 
children. 
Histopathologically, this disease may manifest subepidermal 
bulla formation. A more distinctive feature is the vacuolar and 
necrotic degeneration of the basal cells that leads to epidermal 
necrosis and perivascular infiltration of lymphocytes. 
The diagnosis of erythema multiforme is usually not difficult 
and can be confirmed by routine histopathology. In the past, 
negative direct and indirect immunofluorescent staining have 
been helpful in separating this condition from other subepider-
mal blistering diseases. The demonstration of vessel fluores-
cence, as in other forms of cutaneous vasculitis, is a means of 
separating this condition from other subepidermal blistering 
dermatoses. The identification of the exact underlying cause, 
i.e., drugs, infectious agent, malignancy, etc., is usually more 
difficult. 
Erythema multiforme usually responds to lower doses of 
corticosteroids than other blistering skin diseases do. A short 
course of prednisone starting at 40 mg and tapering over 2 to 3 
weeks is usually sufficient. Elimination of the underlying agent, 
when known, usually stops recurrent episodes. 
Status of research: Erythema multiforme is a reaction pat-
tern in tne skin, probably with a variety of etiologies. Although 
immune mechanisms have long been suspected as the under-
lying cause of erythema multiforme, there have been few basic 
immunologic investigations to substantiate this hypothesis. 
Erythema multiforme may now be added to the list of other 
blistering diseases associated with positive IF findings. In a 
study of 13 patients deposits of C3 and often IgM were found in 
superficial vessel walls of the papillary dermis. Herpes simplex 
virus was thought to initiate the erythema multiforme attacks 
in 6 ofthe 13 patients. Although ofthe IgG class, herpes simplex 
neutralizing antibodies were present in the patients. 
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Reduced levels of Clq, C4, C2, and C3 in blister fluids have 
recently been reported. Cleavage of C3, C4, and factor B was 
also noted, suggestive of local complement activation. When a 
125I_Clq deviation test was used, immune complexes, but not the 
corresponding serum, were detected in blister fluids. These 
studies, suggestive of local complement activation and immune 
complex formation, indicate that the immunopathogenetic 
mechanisms of this disease complex warrants further investi-
gation. 
Dermatitis Herpetiformis 
Prevention, treatment, and cure: Dermatitis herpetiformis is 
a chronic bullous disease that may occur at any age. Untreated 
dermatitis herpetiformis is not fatal. Dermatitis herpetiformis 
is characterized by small groups of tense vesicles on an erythe-
matous base. Symmetrical distribution over the extensor sur-
faces is common, and the buttocks, lower back, and shoulders 
are most severely affected. An intense burning pruritus accom-
panies this disease. Histologically, the lesions demonstrate a 
subepidermal bullous formation . Neutrophilic microabcesses 
are seen in the dermal papillae. 
In addition to the cutaneous manifestations, dermatitis 
herpetiformis is a systemic disease. Biopsies of the small intes-
tine have revealed a patchy duodenal or jejunal atrophy indis-
tinguishable from adult celiac disease. Signs and symptoms of 
a malabsorption syndrome, however, are only occasionally seen 
(perhaps because of the patchy involvement of the gut). 
Diaminodiphenylsulfone (Dapsone), sulfoxone (Diasone), 
and sulfapyridine provide prompt improvement in symptoms 
and signs of the disease; symptoms may abate in as few as 3 
hours or as long as a few days after the fIrst pill is taken; and 
new lesions no longer erupt after 1-2 days of treatment. Exac-
erbations occur from hours to days after cessation oftreatment. 
This response to therapy was, for a long time, the most telling 
evidence in making a diagnosis. The mechanism of action of 
these drugs is unknown. 
The small intestinal lesions in dermatitis herpetiformis re-
spond to withdrawal of gluten from the diet. The temporal 
response to treatment in adult dermatitis herpetiformis is the 
same as that in adult celiac disease. There are conflicting data 
as to the effect of gluten-free diets on the skin lesions. Although 
at first glance this question seems an easy one to answer it is 
not. Dermatitis herpetiformis patients experience diffIculty in 
following a gluten-free diet because they are usually free of 
gastrointestinal symptoms after a short-term treatment. For 
the skin to benefIt the regimen must be continued over a long 
period. Most workers now agree that there is at least a subgroup 
of patients in whom a gluten-free diet helps the skin, although 
there is still debate as to the size of this group and the exact 
meaning of this observation. 
Status of research: IgA deposits are detected by direct im-
munofluorescence and are the most regular finding in patients 
with dermatitis herpetiformis. They are not affected by treat-
ment. One may find C3, fIbrin, and other immunoreactants in 
sites corresponding to the IgA. Circulating antireticulin, anti-
thyroid micro somes, and antinuclear antibodies are also found 
in small but significant numbers. Circulating immune com-
plexes have also been detected in the sera of many patients. 
Serum complement levels, however, are normal. Histocompat-
ibility testing reveals that a high percentage of patients are 
HLA-B8 positive. A signifIcant percentage of patients also have 
achlorhydria and atrophic gastritis. Despite the above evidence 
that dermatitis herpetiformis may be an immunologic disease, 
the etiology remains unknown. 
Direct immunofluorescent studies show that IgA is almost 
always deposited at the dermal-epidermal junction, linear dep-
osition of IgA less commonly, and IgG and IgM deposition 
much less commonly. C3 is often found at sites corresponding 
to IgA deposition. These studies have been interpreted as 
suggesting activation of complement at the site of blister for-
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mation with the subsequent release of chemotactic factors for 
neutrophils. 
To this otherwise straightforward explanation must be added 
one "immunologic" caveat. Immunoreactants, identical quali-
tatively and, as far as one can determine, quantitatively, are 
found in perilesional as well as in normal appearing skin. 
Therefore, one must postulate additional factors to explain the 
initiation of lesions. Little more has been discovered about the 
pathogenesis. 
The incidence of morphological changes in the mucosa of the 
small intestine, almost identical to those in adult celiac disease, 
is very high (90%). This is exemplifIed by both villous blunting 
or flattening and by increased numbers of interepithelial lym-
phocytes. 
Genetic studies have demonstrated that approximately 90% 
of patients with dermatitis herpetiformis have HLA-B8 antigen 
whereas only 20-30% in the general population have it. Ap-
proximately 90% of patients suffering from adult celiac disease 
have this same HLA-B8 antigen. Recent evidence also indicates 
these 2 diseases have in common a very high incidence ofB cell 
surface antigens WI and Bl. 
Dermatitis herpetiformis may be a hypersensitivity disease 
in genetically predisposed individuals. Two speculations on the 
relationship of the gut disease to the skin disease are: l. Antigen 
(perhaps gluten) is presented to the host via the gastrointestinal 
tract, preferentially stimulating the secretory immune system 
(IgA) . Binding of the antigen to IgA in the gut produces the 
patchy duodenal or jejunal atrophy. IgA immune complexes 
then diffuse into the general circulation through the damaged 
mucosa; these IgA complexes circulate to skin where they are 
deposited. Once deposited, they activate the complement sys-
tem via the alternative pathway and produce skin disease. 2. 
The inciting antigen and a normal skin structure-perhaps 
reticulin fIbers-may bear antigenic similarities. Thus, IgA 
directed against the inciting antigen could also cross-react with 
the skin structure. Obviously much more investigation must be 
done before we will fully understand the association of the skin 
and gut in dermatitis herpetiformis. 
Needs for additional basic research: Vesiculobullous dis-
eases. Although these diseases are classifIed as "immunologi-
cal," we do not even know whether the presence of antibodies 
detected in these diseases is a cause or a secondary effect of the 
disease. It is of utmost importance to determine the function of 
antibodies in the vesiculobullous diseases. If antibodies are 
found to be causal, it will then be possible to determine the 
mechanism by which cells are killed, i.e., by antibody-mediated 
cytotoxicity, by immune complex-mediated destruction, by 
complement-mediated destruction, or by lymphocyte-mediated 
destruction. 
There is also a need to identify, isolate, and purify the 
antigens liberated in these diseases. Such information might 
provide a new therapeutic approach by effacing or altering the 
antigen to reduce the immunological reaction. Immune com-
plexes detectable in sera and blister fluids of patients with 
vesiculobullous diseases have not been suffIciently charaterized. 
Particularly the antigenic moieties involved need to be defIned. 
We should develop methods to induce vesiculobullous dis-
eases in laboratory animals. With the isolation and purifIcation 
of responsible antigens, animal model systems will enable more 
productive study of the pathogenesis of these diseases and serve 
as the testing ground for the efficacy of different treatments. 
Certain important specifIc questions need investigation. 
l. The HG factor in patients with herpes gestationis needs 
further characterization, and the involvement of female hor-
mones in HG needs to be established. 
2. IgA found in the skin of patients with dermatitis herpeti-
formis is of unquestioned diagnostic significance. Exactly what 
it does in the disease process needs to be discovered. 
3. The sulfone drugs are effective in treating dermatitis 
herpetiformis, certain other kinds of dermatitis, and leprosy. 
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How they act is unknown. It would be worthwhile to study the 
mechanism of action of these drugs to learn more about the 
pathogenesis of dermatitis. 
4. Many patients with dermatitis herpetiformjs have gluten-
sensitive enteropathy. There are also strong associations of 
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Prevention, Treatment, and Cure 
The exact pathogenetic mechanism by which patients de-
velop lesions of leukocytoclastic vasculitis is not known. How-
ever, current evidence suggests that this form of vasculitis is an 
immune-complex disease (type III immunologic reactionl. thus 
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environment. However, total elimination of an essential insec-
ti.cide from a farmer's environment may not be possible. 
It is important to further determine the common causes of 
vasculitis. If certain chemicals or drugs are incriminated with 
sufficient frequency, it would be appropriate to eliminate those 
compounds from production. 
Status of Research 
Basic research conducted in rabbits has clearly demonstrated 
that renal vasculitis can be reproduced by intravenous injection 
of a preformed antigen antibody complex or by injection of 
appropriate amounts of antigen into an animal with high levels 
of circulating antibody. Studies on th e rabbit model suggested 
that vasodilation or vessel damage was necessary before the 
circulating immune complexes would bind to the vessel wall. 
Once binding occurred, the complement cascade was initiated 
and factors chemotactic for polymorphonuclear leukocytes were 
elaborated. The leukocytes migrated into t he vessel wall where 
they released lysosomal enzymes such as elastase and collagen-
ase, both of which damage the vessel. The damaged vessel wall 
leaked red blood cells into t he surrounding tissue and a marked 
inflammatory inflltrate was formed . Eventually the vessel was 
destroyed, the destruction resulting in necrosis of the surround-
ing t issue. Such necrosis in the skin usually heals leaving only 
a scar that does not impair function. However, such necrosis in 
the kidney can and does markedly impair function and can lead 
to death. In fact, just such an event occurred in the animals 
maintained in a state of antigen excess so that their active 
vasculitis persisted over several weeks. However, rabbits do not 
develop cutaneous lesions so the animal model is not identical 
to the disease as it develops in humans. 
A few interdisciplinary clinical research studies have been 
conducted. One study, of over 60 patients, uncovered a number 
with vasculitis caused by hepatitis B virus. The study demon-
strated, for the fust time, that an immune complex pathogen-
esis, similar to that in rabbits, was also occurring in man. 
Needs for Additional Basic Research 
An animal model that adequately mimics the spectrum of 
vasculitis is a much needed research tool. Such a model would 
make testing of suspected antigens and therapeutic modalities 
possible. The probability of developing a model is reasonable in 
light of our present understanding of thepathomechanism of 
vasculitis. 
Laboratory assays should be developed to differentiate sys-
temically generated cutaneous vascular lesions from those orig-
inating peripherally. Better techniques to identify tissue depos-
ited immune complexes in vasculitis are needed. Assays for 
circulating immune complexes, such as 125I_Clq binding and 
Rajicell binding, and for inhibition for antibody-dependent 
lymphocyte cytotoxicity should be further developed, the goal 
to identify the antigenic moiety of the immune complex. Fur-
ther study is needed to find out how the balance of the clotting 
and the fibrinolytic systems in patients with cutaneous vascu-
litis is altered. More sensitive tissue assays should be developed 
to measure tissue fibrinolysis. How platelets and the platelet 
modulating factors (prostacyclines and thromboxanes) function . 
in vasculitis needs to be studied. 
Needs for Additional Clinical R esearch 
To identify common antigenic chemicals in our environment, 
to delineate the course of vasculitis, and to develop effective 
therapy will require large numbers of patients studied by clin-
ical teams in a prospective manner. Because the disease is 
uncommon, interinstitutional studies will yield the largest num-
ber of patients in the shortest possible t ime. Past studies have 
demonstrated the importance of cooperation of experts in many 
fields. Besides dermatologists, teams should include immunol-
ogists, nephrologists, pathologists, and pediatricians. 
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6. LUPUS ERYTHEMATOSUS 
Prevalence and Severity 
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Lupus erythematosus is a multisystem, chronic, inflamma-
tory disease. It exists in 2 forms: (1) a benign cutaneous disease 
in which the inflammatory process is confined to the skin, 
referred to as discoid lupus erythematosus (DLE) and (2) a 
more serious form termed systemic lupus erythematosus (SLE) 
in which t he disease process primarily involves internal organs. 
Cutaneous lesions are common in SLE. Approximately 20% 
of SLE patients display prominent cutaneous lesions at the 
onset of their disease, and 70-80% of SLE patients will at one 
time during the course oftheir disease demonstrate skin lesions 
the cutaneous features of lupus. ' 
Prevention, Treatment, and Cure 
Pathology: SLE cutaneous lesions vary in their appearance 
from classic discoid and butterfly dermatitis to deep subcuta-
neous nodules; t he intensity of inflammation ranges from mild 
erythema to bulla formation (Table I) . 
Most of the emphasis in research has been on the evaluation 
of the classic discoid lesions. These are coin-shaped, sharply 
demarcated eruptions demonstrating hyperkeratosis, follicular 
plugging, and epidermal atrophy with prominent telangiectasia. 
These lesions are the hallmark of benign cutaneous lupus; they 
are also frequently found in SLE. Histologically, these erup-
tions, like the butterfly malar dermatitis, show orthokeratosis 
and a patchy epidermal atrophy with prominent follicular plug-
ging. Liquifaction of the basal cell layer is diagnostic, and the 
dermis has a patchy mononuclear inflltrate hugging the epider-
mis; there may also be varying degrees of a perivascular mono-
nuclear inflltrate. It is not possible to distinguish clinically or 
histologically those discoid lupus lesions that occur in the 
benign cutaneous lupus from those discoid lesions in systemic 
lupus erythematosus. Discoid lesions of both SLE and DLE 
may be associated with photosensitivity. One recent report 
indicated that when discoid lesions occur in SLE patients they 
are associated with a low prevalence of anti-n-DNA antibodies 
and clinical renal disease. 
Evaluation of other cutaneous lesions occurring in SLE has 
been neglected. Many SLE patients demonstrate evidence of a 
cutaneous vasculitis characterized by microinfarcts at the tips 
of the fingers and periunguinal regions, Janeway spots (tender, 
TABLE L Cutan.eous manifestations of SLE 
Dubois and Tuffa- Rothfield (240 pa-
nelli (520 patients) tients) 
Skin involvement 71.5% 83.3% 
Rash 66.6 
Butterfly dermatitis 36.7 32.5 
Discoid lesions 28.6 15.0 
Maculopapular eruptions 19.0 15.0 
Purpura, ecchymosis, petechae 19.8 6.2 
Urticaria 6.9 9.1 
Bullous lesions 0.4 4.5 
Periungual erythema 1.1 10.0 
Palmar erythema 8.7 
Photosensitivity 9.1 22.0 
Periorbital edema 4.8 5.8 
Facial edema 4.6 18.3 
Hyperpigmentation 8.4 5.8 
Leg ulcers 5.6 9.1 
Alopecia 
Diffuse 21.3 42.4 
Patchy 3.6 9.5 
Both types 7.0 
Mucosal ulcers 9.1 20.4 
Raynaud's Phenomenon 18.4 2.4 
Digital gangrene 1.3 0.8 
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edematous, erythematous papules) on the palms, and Osler 
nodes (tender, erythematous nodules) on the tips of the fingers. 
Other cutaneous manifestations of vasculitis in SLE patients 
are ulcers, lividoreticularis, deep cutaneous nodules, panniculi-
tis, and oral ulcerations. 
Vasculitis can present itself as urticaria and urticarial-like 
plaques in SLE patients. Unlike common urticaria, these lesions 
persist for days and are frequently associated with hypocom-
plementemia. These lesions histologically demonstrate a nec-
rotizing vasculitis characterized by fibrinoid necrosis and a 
prominent polymorphonuclear leukocyte perivascular infiltrate. 
Many of these leukocytes are fragmented (leukocytoclasis). 
The marked variation in the morphologic features of these 
vasculitic lesions are in large part due to two factors. First is 
the level of blood vessel involvement in the skin . Vasculitic 
lesions involving terminal venules or arterioles in the papillary 
portion of the dermis commonly present themselves as pete-
chiae, small infarcts, and ulcers. Vasculitis lesions deeper in the 
dermis, on the contrary, occur in those anatomical regions that 
have substantial collateral circulation. Therefore, these vascu-
litis lesions only occasionally present themselves as infarcts and 
ulcers. Instead, they commonly appear as erythematous, edem-
atous plaques. Second, the intensity of the vasculitis insult 
determines the nature of the lesion. Mild inflammation leads to 
vasodilation and local edema, whereas an intense vasculitis may 
produce infarction of the blood vessel. 
It is impressive that these nondiscoid lupus lesions seem to 
occur in SLE patients and seldom, if ever, in patients with 
benign cutaneous lupus (DLE). In a recent study of 80 patients 
with DLE the lesions of mucous membrane ulceration, Janeway 
spots, Osler's nodes, urticaria ulcers and panniculitis were al-
most nonexistent. Limited experience with these vasculitic le-
sions indicate that they occur in acutely ill SLE patients who 
frequently have arthritis, renal disease, etc. 
Various subsets of SLE have been recognized. They are 
defined to a large extent by the types of antibodies present in 
the patient's serum. Current evidence indicates that they are 
clinically different from one another and, most important, they 
have different prognoses. Several of these subsets have distinc-
tive mucocutaneous features. 
In recent years, evidence has been accumulating that SLE 
patients form antibodies against a variety of cellular macro-
molecules. These include antibodies against single stranded (ss) 
DNA, native (n) DNA, nucleoprotein, histones, and various 
RNA-proteins. Patients with SLE also frequently produce anti-
bodies against the nuclear non-nucleic acid macromolecules 
Sm, ssB, Ha, and the non-nucleic acid cytoplasmic component 
Ro. 
Antibodies directed against nuclear RNP and Sm are also 
found in patients that have high-titered antibodies against 
soluble extractable nuclear antigens (ENA). The antibodies for 
nuclear ribonucleic acid protein have been reported in patients 
with the mixed connective tissue syndrome and SLE. 
Antibodies against Sm, a nuclear non-nucleic acid glycopro-
tein, show a high degree of specificity for SLE patients. Prelim-
inary evidence indicates that the Sm antibody can be detected 
in a subset of SLE patients with hypocomplementemia and 
mild renal disease. 
Those SLE patients possessing only anti-RNP antibodies 
have a disease process characterized by a significantly lower 
incidence of renal disease. One recent study has demonstrated 
that anti-RNP SLE patients with renal disease always have 
other serum antibody systems in addition to n-RNP. SLE 
patients with anti-RNP antibodies have a higher incidence of 
myositis, Raynaud's phenomena, scleroderma-like features and 
the sicca syndrome. 
Antibodies against nDNA app·ear to be more prevalent in 
those SLE patients who have hypocomplementemia and active 
renal disease, and anti-nDNA antibodies have been eluted in 
high concentration from the kidneys of SLE patients dying with 
lupus nephritis. 
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The ssB (Ha) antibody system has recently been described. 
This antibody system, reactive against a soluble acid nuclear 
protein, has been found thus far only in patients with Sjogren's 
syndrome and approximately 10-15% of patients with SLE. 
Preliminary studies indicate that SLE patients possessing this 
antibody system have a high incidence of the sicca syndrome. 
Antibodies directed against the cytoplasmic non-nucleic acid 
macromolecule Ro are found in approximately 25% of SLE 
patients. SLE patients possessing anti-Ro antibodies have an 
increased prevalence of Sjogren's syndrome, photosensitive der-
matitis, and clinical renal disease. A history of photosensitivity 
was found in approximately 60% of SLE patients with, and in 
25% without, anti-Ro antibodies. One recent report has de-
scribed a group of Ro positive lupus patients with prominent 
photosensitive dermatitis who failed to demonstrate antinuclear 
antibodies by routine immunofluorescent techniques. 
Treatment: The cutaneous lesions of lupus erythematosus 
have a varied response to therapy. Topical fluorinated steroids 
are probably the most common anti-inflammatory preparation 
employed for the treatment of the cutaneous lesions of lupus. 
Intralesional steroid injections and, more recently, steroid im-
pregnated tapes have become a popular and successful means 
of treating cutaneous lupus. 
Widespread photosensitive lupus, however, demands the use 
of parenteral anti-inflammatory agents. This commonly takes 
the form of prednisone in doses ranging from 20-60 mg daily, 
usually given over a short period of time with the hope of 
aborting the potential scarring and disfiguring qualities of the 
inflammatory dermatoses. Many physicians also prescribe the 
antimalarial, plaquenil. Patients are warned about sun exposure 
as this may flare their systemic disease. It must be pointed out 
that all lupus lesions left untreated may leave the patient with 
objectionable scars. 
Some of the more inflammatory photosensitive lesions, un-
fortunately, demand long-term maintenance on corticosteroids 
and antimalarials. In patients with SLE, the skin lesions are 
often controlled by the systemic therapy that the patient re-
ceives for the internal disease. 
Status of Research 
The pathogenesis of the classic discoid and butterfly lesions 
are, at present, unknown. Early experimental work demon-
strated that various immunoglobulins were deposited along the 
dermal-epidermal junction of affected skin. All complement 
components including proteins of the alternative complement 
pathway of activation together with fibrin have been detected, 
and the incidence of these immunoreactants in lesional skin is 
as high as 90%. However, very young and very old lesions 
frequently fail to demonstrate these findings. 
By employing DNA, which has previously been denatured by 
ultraviolet light, and then coupling this to methylated bovine 
serum albumin, similar immunofluorescent lesions have been 
produced in mice previously sensitive to UV-DNA. These mice, 
developed immunoglobulin deposits at the dermal-epidermal 
junction upon exposure to UVL, their skin quickly displayed 
erythema following UVL, and their lesions demonstrated a 
polymorphonuclear perivascular infiltrate. Epidermal degener-
ation was also noted. Unfortunately, the progression of clinical 
and histological features of the skin lesions were not observed. 
It is doubtful, however, that this mouse model is analagous to 
the discoid lupus lesions since the experimental model displayed 
a prominent polymorphonuclear and not the mononuclear in-
filtrate of human lupus. 
Examination of female NZB/NZW FI hybrid mice has also 
provided potentially valuable data regarding the pathogenesis 
of discoid lupus lesions. These animals develop a multisystem 
disease remarkably similar to SLE and a fatal glomerulone-
phritis and anti-nDNA antibodies. In addition, they display Ig 
deposits along the dermal-epidermal junction. The skin, how-
ever, fails to show either morphologic or histologic evidence of 
inflammation. 
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Studies cast doubt on the role of Ig and complement in t he 
pathogenesis ofthe discoid lupus lesions. The usual clinical and 
histological discoid lupus lesions were not induced in SLE 
patients exposed to UVL. However, immunoglobulin deposition 
in t h ese experimentally-induced lupus lesions occurred only 
?-fter the dermatitis was well-established. In several instances, 
Immunoglobulin deposition could not be detected 2 to 3 months 
after the development of a clinical lesion. 
Work by a number of investigators has demonstrated that 
immunoglobulin and complement deposition frequently occurs 
along the dermal-epidermal junction of normal-appearing skin 
in SLE patients. Furthermore, histologic examination of this 
normal skin fails to reveal evidence of inflammation. 
Discoid lupus-like lesions frequently occur in patients with 
various hereditary deficiencies of the complement system, an-
other piece of evidence suggesting that immunoglobulins and 
complement may not playa primary role in the pathogenesis of 
discoid lupus. 
Finally, the classic discoid lupus lesion is characterized by 
basal cell degeneration and a mononuclear cell infIltrate. A 
similar injury pattern is seen in animal and human graft-versus-
host diseases in which it is known that injury is mediated by 
cells, not immunoglobulins or complement. 
The evidence summarized above strongly suggests that de-
posits of immunoglobulin and complement, so commonly ob-
served in discoid lesions, are not primarily responsible for the 
pathogenesis of these lesions. At present, our best guess is that 
cell mediated immunity may be pathogenetically significant in 
the genesis of discoid lupus lesions; however, data to support 
such a hypothesis are not available. 
The vasculitic lesions of SLE have been little studied, and 
detailed histologic data is lacking. Immunofluorescent studies 
have not been extensive, although several reports indicate that 
immunoglobulins and complement are found in and about 
damaged blood vessels. This suggests a function of immune 
complexes in the pathogenesis of these vasculitis lesions. Much 
more work must be done to substantiate this hypothesis. 
Laboratory abnormalities: The diagnosis of cutaneous LE is 
usually made by histologic examination. At times, it is difficul t 
to differentiate the cutaneous lesions of lupus erythematosus 
from polymorphic light eruptions and benign lymphocytic infIl-
trate of J essner, etc. In these instances, direct immunofluores-
cent examination of the involved skin has proved to be a 
valuable diagnostic tool. The test is highly specific for DLE. 
Few false positives have been detected. The positive immuno-
fluorescence in lichen planus and porphyria cutanea tarda are 
easily distinguished by an experienced immunofluorescent mi-
croscopist. 
In recent years, direct immunofluorescent examination of 
norunvolved skin of patients suspected of having systemic lupus 
erythematosus has been employed as a diagnostic tool to distin-
guish DLE from SLE. Immunoglobulin and complement dep-
osition at the dermal-epidermal junction is detected only in the 
involved areas of DLE patients. It is detected in t he normal as 
well as in the involved areas of SLE patients (see Table II). 
The direct immunofluorescent detection of Ig and comple-
ment deposition along the dermal-epidermal junction of non-
involved skin of SLE patients, the lupus band test (LBT), is 
highly specific for SLE. These deposits contain IgA, IgG, IgM 
classical and alternative complement pathway proteins and 
fibrin. Antinuclear antibody specificity has been demonstrated 
in eluates of these deposits. The incidence of positivity varies 
with the site of biopsy. Biopsies taken from the buttocks, the 
volar aspect of forearm, and the deltoid region exhibit a positive 
LBT incidence of 40, 55, and 90 percent respectively. The 
reasons for this variation from biopsy site to biopsy site is 
unknown although it may be related to the local rate of epider-
mal proliferation. Areas with an increased epidermal prolifera-
tion have an increased incidence of a positive LBT. Additional 
evidence from several laboratories indicates that a positive LBT 
correlates with the presence of anti-DNA antibodies. Recently 
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TABLE II. Direct immunofluorescence in lupus erythematosus 
Clinical diagnosis Biopsies #- Positive % Positive 
SLE 
Involved skin 150 135 90 
Uninvolved skin 198 108 54 
DLE 
Involved skin 234 216 90 
Uninvolved skin 52 0 0 
it has also been demonstrated that DNA, both single-stranded 
and native DNA, binds to the collagen at the junction of the 
dermis and epidermis. These data collectively suggest that the 
mechanism for the deposition of Ig and C at the dermal-epider-
mal JunctIOn of SLE normal skin may be dependent upon the 
following sequence of events. First, epidermal proliferation with 
increased DNA synthesis may be the primary source of DNA 
found in a positive LBT. Next, the epidermal DNA released 
during proliferative response (or by trauma, UVL, etc.) binds 
to the collagen at the dermal-epidermal junction. Then, the 
DNA complexes with t he serum anti-DNA antibody. Thus, the 
LBT may be an in vivo assay for DNA binding. 
LBT as a prognostic test to segregate those who have a 
greater r isk of developing renal disease is controversial. Some 
have observed that SLE patients possessing a positive LBT had 
a higher incidence of renal disease, hypocomplementemia and 
a peripheral pattern ANA (anti-nDNA). Others disputed these 
observations because the number of SLE patients examined 
with renal disease was small or the patients had been on therapy 
when examined. Data from several laboratories indicated that 
LBT is dynamic and will disappear with immunosuppressive 
and/ or steroid therapy. 
Several studies on the large number of untreated SLE pa-
tients have indicated the following LBT correlations. 
l. A negative LBT is associated with a group of SLE patients 
demonstrating a low incidence of renal disease . . 
2. A positive LBT containing only IgM is found in a group of 
SLE patients with a low incidence of renal disease. 
3. A positive LBT containing IgG alone or IgG plus other Ig 
classes is associated with a group of SLE patients with a greater 
incidence of renal disease. 
Needs for Additional Basic Research 
An alteration in cell-mediated immune mechanisms may be 
operative in the pathogenesis of lupus erythematosus. Cell-
mediated immunity may also take part in producing cutaneous 
lesions. By locating aQtigenic sites of cell-mediated immunolog-
ical reactions we might determine whether DNA or other 
antigens are responsible for skin lesions. It is recommended 
that cell-mediated immune techniques be used to induce discoid 
lupus lesions in animal models. 
Although immunoglobulin deposits in the skin of patients 
with lupus erythematosus may have no bearing on the patho-
genesis of skin lesions, we should determine thei.r specific anti-
body nature and, more important, discover the antigen to which 
these complexes are bound. Such findings would undoubtedly 
relate to types of immune complexes present in the serum and 
kidneys of SLE patients. 
The New Zealand black mouse, a very useful animal model 
of lupus erythematosus, has immunoglobulin deposits at the 
basement membrane zone of the epidermis and' kidney. Studies 
on these animals should be undertaken to determine (1) the 
relationship of these immune deposits to renal disease and to 
serum auto-antibody production and (2) how the complexes are 
altered by various treatment modalities. 
Needs for Additional Clinical Research 
The most pressing need is to develop therapeutic modalities 
safer and more effective tha n corticosteroids. These should be 
tested first by trials with New Zealand black mice and then by 
careful studies with human patients. 
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There is no doubt that ultraviolet B is deleterious to patients 
with lupus; how the damage occurs is unknown. We need to 
pursue studies that examine the relationship of ultraviolet light 
to the development of lupus skin lesions. Such studies might 
not only result in ways to protect patients from sun exposure 
but might also throw light on the pathogenesis of lupus. 
Clinical correlation should be obtained of the degree of dis-
ease activity of nondiscoid lupus lesions to the presence of 
specific serum antibodies and to the presence or absence of 
serum immune complexes. Lupus-like lesions are frequently 
seen in patients with heritable deficiencies of the complement 
system. A study of these patients might provide insight into 
those mechanisms of immunological injury that result in lupus 
erythematosus of the skin. 
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